Synthesis of Trifluoromethyl Substituted Allenols via Catalytic Trifluoromethylbenzoxylation of 1,3-Enynes

Supporting Information

Songrong Li,^{a†} Wenwen Yang,^{a†} Junjie Shi,^a Tingting Dan,^a Yujie Han,^a Zhi-Chao Cao,^{*b} and Mingyu Yang, ^{*a}

[a] Key Laboratory of Applied Surface and Colloid Chemistry of MOE, School of Chemistry and Chemical Engineering, Shaanxi Normal University, Xi'an, 710119, China Email: <u>yangmy05@snnu.edu.cn</u>

[b] Anhui Agricultural University, Hefei, Anhui, China230036

E-mail: zc_cao@ahau.edu.cn

Table of Contents

Instrumentation and Chemicals	S1–S2
Preparation of Togni's Reagent and 1,3 - Enynes	S3–S5
Characterization Data for 1,3 - Enynes	S5–S13
General Procedure for 1, 4-functionalization of 1,3 - Enynes	S14
Characterization Data for Products	S14–S28
Late-stage functionalization of allene compounds	S28–S35
NOESY Experiments	S36
Characterization Data for 1,3-dienes	S37–S45
Mechanism Study	S45-S52
References	S52-S53
NMR Spectra	S54–S155

Instrumentation and Chemicals

NMR spectra were recorded on Bruker 400 M and 600 M, JEOL 400 M spectrometers, operating at 400 and 600 MHz for ¹H NMR, 100 and 150 MHz for ¹³C NMR spectrophotometer, 376 MHz for ¹⁹F NMR using CDCl₃ and TMS as the internal standard. Chemical shift values for ¹H and ¹³C are referenced to residual solvent peaks (CHCl₃ in CDCl₃: 7.26 ppm for ¹H, 77.00 ppm for ¹³C; Chemical shifts are reported in δ ppm. All coupling constants (*J* values) were reported in Hertz (Hz). Data for ¹H NMR spectra are reported as follows: chemical shift (ppm, referenced to TMS; s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, dt = doublet of triplets, m = multiplet), coupling constant (Hz) and integration. Column chromatography was performed on silica gel 200-300 mesh. High-resolution mass spectra (HRMS) were recorded on electron-spray ionization (ESI) technique or Atmospheric Pressure Chemical Ionization (APCI) technique. Ultra-high resolution mass spectrometer (FT-ICR-MS).

Experimental Section

All reactions were carried out under nitrogen atmosphere. Materials were obtained from commercial suppliers or prepared according to standard note procedures unless otherwise noted. CuI was purchased from Energy Chemical Reagent Co., Ltd., Pd(PPh₃)₄ was purchased from, DCE was freshly distilled over CaH₂ under N₂. Energy Chemical Reagent Co., Ltd. EDC·HCl was the abbreviations of 1-(3-dimethylaminopropyl) -3-ethylcarbondiimide hydrochloride, it was purchased from Energy Chemical Reagent Co., Ltd.; HOBt was the abbreviations of 1-Hydroxybenzotriazole, it was was purchased from Energy Chemical Reagent Co., Ltd..

General Procedure A: Preparation of 1,3 – Enynes^[2]

$$R^{1} + Br R^{2} R^{3}$$


$$Cul 10\% Pd(PPh_{3})_{4} 2\% R^{1} R^{2} R^{2}$$

$$R^{1} R^{2} R^{3}$$

$$R^{1} R^{2} R^{3} R^{3}$$

Alkenyl bromide (1.1 equiv, 15 mmol) was added to a solution of $Pd(PPh_3)_4$ (231 mg, 0.20 mmol) and CuI (189 mg, 1.0 mmol) in piperidine (20 mL). The solution was stirred for 5 min, then Terminal alkyne (1.0 equiv, 10 mmol) was added, and the mixture was stirred at 60 °C for 2 h. The mixture was cooled to room temperature, and saturated aqueous NH₄Cl solution (50 mL) was added. The mixture was extracted with petroleum ether (3 × 20 mL) and the combined organic phases washed with brine (20 mL), dried (Na₂SO₄), filtered, and concentrated in vacuo. The mixture was purified by column chromatography (100% petroleum ether) to give1,3-enynes as a Colourless oil.

Preparation of 1y:




Triethylamine was added (2.04 g, 20 mmol) to a solution of lithocholic acid (1.88 g, 5.0 mmol) in DMF (14.0 mL). And then, benzyl bromide (1.3 mL, 11 mmol) was slowly added to the reaction mixture. The resulting solution was stiring room temperature for 5 hours. The reaction was quenched by water and extracted with ethyl acetate (3×50 mL). Combining the organic phase and dried with magnesium sulfate and evaporated the solvent under vacuum to give residue. The residue was purified by chromatography on silica gel (ethyl acetate/hexane 1:9 to 1:1) to obtain the product **II**. EDC·HCl (1.5

equiv.) and HOBt (0.5 equiv.) were added to a solution of **II** (1 equiv.) and propargyl amine (1.1 equiv.) in dry DMF (5 mL) under argon at 0 °C. After the addition, there reaction mixture was allowed to warm up to 25 °C and was stirred for 12 h. The reaction was quenched by adding crushed ice and extracted three times with ethyl acetate. The combined extracts were washed with water and brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The resulting crude product was purified by column chromatography to give pure alkyne compounds **III**. Compound **1z** was followed the same procedure as preparation of 1,3 - enynes.


1,3 - Enynes, 1a,^[2] 1b,^[2] 1c,^[2] 1d,^[2] 1e,^[3] 1f,^[3] 1g,^[7] 1h,^[3] 1i,^[5] 1j,^[5] 1k,^[5] 1l,^[4] 1n,^[7] 1o,^[4] 1r,^[4] 1t,^[4] 1u,^[4] 1v,^[3] 1w^[3] can be found in literatures.

General Procedure B: Preparation of bromide^[8]



A suspension of (Ph₃PCH₂Br)Br (28.0 g, 64.2 mmol, 8.0 equiv) in dry toluene (200 mL) was sonicated for 30 min at rt and then stirred at -15 °C for 15 min. Then KO^tBu (7.10 g, 63.2 mmol, 5.9 equiv) was added. The yellow mixture was stirred at -15 °C for 3 h. Then a 0 °C cooled solution of ketone (10.07 mmol, 1.0 equiv) in dry toluene (100 mL) was added dropwise via cannula. The reaction mixture was stirred at -10 °C for 1 h and then without cooling bath for 1.5 h. The reaction was quenched by a few drops of saturated NH₄Cl. The mixture was filtered through a short pad of silica gel washing with hexanes. Concentration gave a residue which was purified by flash chromatography (hexanes) to afford bromide.

General Procedure C: Preparation of Togni's Reagent^[9] (2)




NaIO₄ (7.24 g, 33.8 mmol) and 2-iodobenzene (I) (8 g, 32.2 mmol) were added to 50 mL of 30% (v/v) AcOH and refluxed for 4 hours with vigorous stirring. The reaction mixture was then diluted with 180 mL of cold water, cooled to room temperature, and the crude was collected via suction filtration. The crude white solid was washed with cold water (10 mL \times 3) and acetone (10 mL \times 3), and air dried in the dark overnight to afford compound II.

Compound II (6.00 g, 21.1 mmol) was refluxed in Ac₂O until the solution became clear. The reaction mixture was then cooled slowly to -20 °C for 4 hours using a dry ice/ethylene glycol: ethanol (9:1) bath. The solution was decanted, and the white solid (III) was dried under vacuum with stirring for 24 hours.

Compound **III** was dissolved in 50 mL of dry MeCN (under Ar). To the mixture, trimethyl (trifluoromethyl) silane (4.5 mL, 30.4 mmol) and cesium fluoride (0.05 g, 0.33 mmol) were added under argon. The reaction mixture was then stirred vigorously at room temperature for 22 hours. The solvent was removed using a rotovap, and the mixture was purified by column chromatography (CH₂Cl₂: MeOH = 15:1) to afford the final product **2** as a pure white solid (4.5 g, 67% isolated yield from **II**).


Characterization Data for 1,3 – Enynes

2-methylnon-2-en-4-yne (1a)




Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.24 (s, 1H), 2.33 (t, *J* = 6.6 Hz, 2H), 1.87 (s, 3H), 1.77 (s, 3H), 1.53 (dd, *J* = 15, 7.2 Hz, 2H), 1.44 (dd, *J* = 15, 7.2 Hz, 2H), 0.92 (t, *J* = 7.2 Hz, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 146.56, 105.46, 92.12, 78.38, 31.14, 24.58, 21.96, 20.70, 19.18, 13.60.

2-methyldec-2-en-4-yne (1b)



Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.24 (s, 1H), 2.33 (t, *J* = 6.6 Hz, 2H), 1.87 (s, 3H), 1.77 (s, 3H), 1.53(dd, *J* = 15, 7.2 Hz, 2H), 1.39 (dd, *J* = 8.4, 7.2 Hz, 2H), 1.33 (dd, *J* = 15, 7.2 Hz, 2H), 0.90 (t, *J* = 7.2 Hz, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 146.55, 105.46, 92.18, 78.37, 31.08, 28.74, 24.57, 22.21, 20.68, 19.46, 13.96.

2-methylundec-2-en-4-yne (1c)




Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.24 (s, 1H), 2.33 (t, *J* = 6.4 Hz, 2H), 1.87 (s, 3H), 1.77 (s, 3H), 1.53 (dd, *J* = 15.3, 5.1 Hz, 2H), 1.38–1.43 (m, 2H), 1.27– 1.32 (m, 4H), 0.89 (t, *J* = 7.2 Hz, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 146.57, 105.46, 92.19, 78.39, 31.37, 29.02, 28.57, 24.58, 22.56, 20.69, 19.50, 14.03.

2,7-dimethyloct-2-en-4-yne (1d)




Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.25 (s, 1H), 2.21–2.29 (d, *J* = 6.4 Hz, 2H), 1.88 (s, 3H), 1.80–1.85 (m, 1H), 1.78 (s, 3H), 0.97–1.00 (d, *J* = 6.6 Hz, 6H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 146.56, 105.48, 91.01, 79.25, 28.71, 28.29, 28.03, 24.57, 21.99, 20.72.

(5-methylhex-4-en-2-yn-1-yl)cyclopentane(1e)



Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.24 (s, 1H), 2.70–2.79 (m, 1H), 1.92 (m, 3H), 1.86 (s, 3H), 1.77 (s, 3H), 1.73 (m, 3H), 1.58–1.66 (m, 3H), 1.55 (m, 1H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 146.51, 105.50, 96.45, 82.22, 76.83, 64.74, 34.16, 33.60, 31.00, 30.53, 24.98, 24.61, 20.71.


(5-methylhex-4-en-2-yn-1-yl)cyclohexane(1f)



1f

Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.24 (s, 1H), 2.22 (d, *J* = 6.6 Hz, 2H), 1.87 (s, 3H), 1.82 (d, *J* = 11.7 Hz, 2H), 1.77 (s, 3H), 1.69–1.75 (m, 2H), 1.62–1.68 (m, 1H), 1.43–1.52 (m, 1H), 1.21–1.29 (m, 2H), 1.10–1.19 (m, 1H), 1.01 (ddd, *J* = 24.6, 12.6, 3.3 Hz, 2H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 146.61, 105.76, 91.16, 79.45, 37.85, 32.93, 27.56, 26.51, 26.38, 24.75, 20.94.


(6-methylhept-5-en-3-yn-1-yl)benzene(1g)




Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 7.27 (t, *J* = 7.5 Hz, 2H), 7.22 (d, *J* = 7.5 Hz, 2H), 7.19 (t, *J* = 7.5 Hz, 1H), 5.22 (s, 1H), 2.85 (t, *J* = 7.5 Hz, 2H), 2.62 (d, *J* =

7.5 Hz, 2H), 1.82 (s, 3H), 1.76 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ= 146.98, 140.81, 128.41, 128.27, 126.13, 105.27, 91.12, 79.07, 35.44, 24.57, 21.67, 20.67.

(4-methylpent-3-en-1-yn-1-yl)cyclopropane(1h)




Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.19 (s, 1H), 1.85 (s, 3H), 1.76 (s, 3H), 1.33–1.43 (m, 1H), 0.79 (dd, *J* = 8.1 Hz, 2.4 Hz, 2H), 0.68 (dd, *J* = 4.8, 2.4 Hz, 2H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 147.00, 105.28, 95.15, 73.65, 24.58, 20.72, 8.57, 0.23. **8-chloro-2-methyloct-2-en-4-yne(1i)**



Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.23 (s, 1H), 3.68 (t, *J* = 6.3 Hz, 2H), 2.53 (t, *J* = 6.6 Hz, 2H), 1.99 (p, *J* = 6.6 Hz, 2H), 1.87 (s, 3H), 1.78 (s, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ =147.35, 105.14, 89.74, 79.42, 43.76, 31.72, 24.60, 20.78, 16.96.


2-(5-methylhex-4-en-2-yn-1-yl)isoindoline-1,3-dione(1j)



1j

White gam. ¹**H NMR** (600 MHz, CDCl₃) δ = 7.88 (dd, *J* = 5.4, 3.0 Hz, 2H), 7.73 (dd, *J* = 5.4, 3.0 Hz, 2H), 5.20 (s, 1H), 4.60 (s, 2H), 1.86 (s, 3H), 1.77 (s, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 167.16, 150.03, 134.05, 132.18, 123.46, 104.40, 84.36, 81.19, 28.03, 24.73, 21.04.


4-methyl-N-(5-methylhex-4-en-2-yn-1-yl)benzenesulfonamide(1k)



Yellow oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 7.78 (d, *J* = 7.8 Hz, 2H), 7.30 (d, *J* = 7.8 Hz, 2H), 5.03 (s, 1H), 4.59 (s, 1H), 3.98 (d, *J* = 5.1 Hz, 2H), 2.42 (s, 3H), 1.75 (s, 3H),


1.71 (s, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 149.89, 143.85, 136.90, 129.86, 127.59, 104.30, 85.07, 83.04, 34.18, 24.93, 21.73, 21.09.

tert-butyl (5-methylhex-4-en-2-yn-1-yl)carbamate(11)



Yellow oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.23 (s, 1H), 4.74 (s, 1H), 4.06 (s, 2H), 1.87 (s, 3H), 1.79 (s, 3H), 1.45 (s, 9H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 155.30, 149.00, 104.59, 87.10, 81.17, 79.77, 31.35, 28.35, 24.70, 20.91.


N-(5-methylhex-4-en-2-yn-1-yl)benzamide (1m)



1m


Yellow oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.79 (d, *J* = 7.2 Hz, 2H), 7.50 (t, *J* = 7.5 Hz, 1H), 7.43 (t, *J* = 7.5 Hz, 2H), 6.35 (s, 1H), 5.26 (s, 1H), 4.40 (d, *J* = 3.0 Hz, 2H), 1.89 (s, 3H), 1.80 (s, 3H). ¹³**C** NMR (150 MHz, CDCl₃) δ = 166.96, 149.55, 134.00, 131.61, 128.55, 126.96, 104.42, 86.34, 81.80, 30.82, 24.73, 21.00. **IR** (KBr, cm⁻¹): 3418, 1641, 1400, 1111, 617. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₁₄H₁₅NNaO, 236.1046; found, 236.1044.

6-methylhept-5-en-3-yn-1-ol(1n)




Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.24 (s, 1H), 3.74 (q, *J* = 6.3 Hz, 2H), 2.62 (t, *J* = 5.4 Hz, 2H), 1.88 (s, 3H), 1.79 (s, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ = 147.93, 104.96, 87.90, 80.52, 61.36, 24.67, 23.95, 20.88.

8-methylnon-7-en-5-yn-1-ol(10)




Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) *δ*= 5.23 (s, 1H), 3.69 (t, *J* = 6.3 Hz, 2H), 2.39 (t, *J* = 6.1 Hz, 2H), 1.87 (s, 3H), 1.78 (s, 3H), 1.68–1.74 (m, 2H), 1.60–1.67 (m, 2H). ¹³**C NMR** (150 MHz, CDCl₃) *δ*= 146.87, 105.33, 91.57, 78.83, 62.52, 31.92, 25.28, 24.59, 20.75, 19.29.

tert-butyldimethyl((6-methylhept-5-en-3-yn-1-yl) oxy)silane (1p)




Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.22 (s, 1H), 3.74 (t, *J* = 7.2 Hz, 2H), 2.55 (s, 2H), 1.86 (s, 3H), 1.77 (s, 3H), 0.90 (s, 9H), 0.07 (s, 6H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 147.17, 105.24, 88.63, 79.49, 62.27, 25.90, 24.60, 23.94, 20.78, 18.33, -5.28. **IR** (KBr, cm⁻¹): 3417, 1619, 1400, 1109, 615. **HRMS-APCI**(m/z): [M+H]⁺ calcd. for C₁₄H₂₇NOSi, 239.1826; found, 239.1826.

triisopropyl((6-methylhept-5-en-3-yn-1-yl)oxy)silane (1q)



Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.22 (s, 1H), 3.82 (t, *J* = 7.2 Hz, 2H), 2.58 (t, *J* = 7.2 Hz, 2H), 1.86 (s, 3H), 1.77 (s, 3H), 1.07 (s, 21H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 147.13, 105.25, 88.63, 79.45, 62.52, 24.59, 24.01, 20.76, 17.95, 11.98. **IR** (KBr, cm⁻¹): 3417, 2944, 2868, 1721, 1627, 1464, 1386, 1251, 1111, 884, 683. **HRMS**-**ESI**(m/z): [M+Na]⁺ calcd. for C₁₇H₃₂NNaOSi, 303.2115; found, 303.2118.


2-((6-methylhept-5-en-3-yn-1-yl) oxy)tetrahydro-2H-pyran(1r)



Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.22 (s, 1H), 4.66 (t, *J* = 3.6 Hz, 1H), 3.89 (s, 1H), 3.82–3.86 (m, 1H), 3.56–3.60 (m, 1H), 3.52 (s, 1H), 2.62–2.66 (m, 2H), 1.87 (s, 3H), 1.77 (s, 3H), 1.69–1.74 (m,1H), 1.57–1.62 (m, 2H), 1.49–1.54 (m, 2H).


¹³C NMR (150 MHz, CDCl₃) δ= 147.21, 105.25, 98.74, 88.51, 79.36, 66.09, 62.14, 30.58, 25.44, 24.57, 20.99, 20.72, 19.38.

6-methylhept-5-en-3-yn-1-yl pivalate (1s)




Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.22 (s, 1H), 4.17 (t, *J* = 6.9 Hz, 2H), 2.66 (td, *J* = 6.6, 1.5 Hz, 2H), 1.86 (s, 3H), 1.78 (s, 3H), 1.21 (s, 9H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 178.32, 147.71, 105.01, 87.20, 79.74, 62.51, 38.70, 27.12, 24.60, 20.75, 19.97. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₁₃H₂₀NaO₂, 231.1356; found, 231.1361.

6-methylhept-5-en-3-yn-1-yl 4-methylbenzenesulfonate(1t)




Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 7.80 (d, *J* = 8.1 Hz, 2H), 7.34 (d, *J* = 8.1 Hz, 2H), 5.15 (s, 1H), 4.11 (t, *J* = 7.2 Hz, 2H), 2.70 (t, *J* = 6.3 Hz, 2H), 2.45 (s, 3H), 1.82 (s, 3H), 1.77 (s, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 148.46, 144.84, 133.00, 129.84, 127.94, 104.68, 85.26, 80.68, 68.01, 24.65, 21.62, 20.83, 20.46.

6-methylhept-5-en-3-yn-1-yl benzoate(1u)




Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 8.06 (d, J = 7.2 Hz, 2H), 7.56 (t, J = 7.2 Hz, 1H), 7.44 (t, J = 7.2 Hz, 2H), 5.23 (s, 1H), 4.44 (t, J = 6.6 Hz, 2H), 2.82 (t, J = 6.6, 2H), 1.85 (s, 3H), 1.78 (s, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 166.35, 147.96, 132.97, 130.09, 129.65, 128.31, 104.98, 87.07, 80.02, 63.17, 24.62, 20.77, 20.13.

hept-2-yn-1-ylidenecyclohexane (1v)




Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.18 (s, 1H), 2.35–2.41 (m, 2H), 2.32 (td, *J* = 7.2, 2.1 Hz, 2H), 2.13 (t, *J* = 6.0, 2H), 1.54–1.60 (m, 4H), 1.48–1.54 (m, 4H), 1.42 (dt, *J* = 14.1, 7.2 Hz, 2H), 0.92 (t, *J* = 7.2, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 153.87, 101.80, 91.87, 77.82, 35.73, 31.25, 31.09, 28.17, 27.40, 26.33, 21.95, 19.19, 13.57.

(3-methyldec-3-en-5-yn-1-yl)benzene (E,Z mixture 3:2)




Yellow oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.25–7.29 (m, 2H×3/5, 2H×2/5), 7.21– 7.24 (m, 1H×3/5, 1H×2/5), 7.16–7.19 (m, 2H×3/5, 2H×2/5), 5.27–5.29 (m, 1H×3/5, 1H×2/5), 2.71–2.76 (m, 2H×3/5, 2H×2/5), 2.57–2.59 (m, 1H×3/5, 1H×2/5), 2.31– 2.37 (m, 3H×3/5, 3H×2/5), 1.91 (s, 3H×3/5), 1.77 (s, 3H×2/5), 1.50-1.53 (m, 2H×3/5, 2H×2/5), 1.41-1.45 (m, 2H×3/5, 2H×2/5), 0.92 (t, *J* = 7.2 Hz, 3H×3/5), 0.91 (t, *J* = 7.2 Hz, 3H×3/5). ¹³C NMR (150 MHz, CDCl₃) δ = 149.59,149.39, 128.34×2, 128.26× 2, 128.24×2, 125.81, 125.78, 106.20, 105.60, 92.99, 92.59, 78.24, 78.05, 40.38×2, 36.49×2, 34.30, 34.03, 31.10, 22.55, 21.98, 21.96, 19.22, 19.16, 13.60×2. IR (KBr, cm⁻¹): 3754, 3655, 2931, 1457, 1369, 698. HRMS-ESI(m/z): [M+H]⁺ calcd. for C₁₇H₂₃, 227.1794; found, 227.1795.

(3R,5R,10R,13R,17R)-5,10,13-trimethyl-17-((R)-5-((5-methylhex-4-en-2-yn-1-yl) amino)-5-oxopentan-2-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl benzoate (1y)




Yellow foam. ¹H NMR (600 MHz, CDCl₃) δ = 8.05 (d, *J* = 7.5 Hz, 2H), 7.54 (d, *J* = 7.5 Hz, 1H), 7.43 (t, *J* = 7.5 Hz, 2H), 5.70 (s, 1H), 5.23 (s, 1H), 4.97 (s, 1H), 4.19 (d, *J* = 3.3 Hz, 2H), 2.26 (s, 1H), 2.17 (s, 1H), 2.08 (ddd, *J* = 18.0, 12.3, 6.9 Hz, 1H), 1.97 (d, *J* = 12.3 Hz, 2H), 1.88 (s, 3H), 1.83–1.89 (m, 4H), 1.80 (s, 3H), 1.69 (s, 1H), 1.51–1.60 (m, 3H), 1.36–1.50 (m, 5H), 1.35 (s, 1H), 1.22–1.31 (m, 3H), 1.18 (d, *J* = 2.6 Hz, 1H), 1.03–1.17 (m, 5H), 0.96 (s, 3H), 0.92 (d, *J* = 6.3 Hz, 3H), 0.65 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 172.97, 166.09, 149.26, 132.63, 130.90, 129.47, 128.20, 104.45, 86.61, 81.40, 74.96, 56.45, 56.04, 42.72, 41.93, 40.45, 40.12, 35.78, 35.46, 35.05, 34.61, 33.37, 32.33, 31.61, 30.16, 28.21, 27.02, 26.73, 26.30, 24.70, 24.15, 23.33, 20.94, 20.84, 18.36, 12.02. **IR** (KBr, cm⁻¹): 3459, 2937, 1715, 1450, 1275, 1114, 713, 616. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₃₈H₅₃NNaO₃, 594.3918; found, 594.3927.

General Procedure for 1, 4-functionalization of 1,3-Enynes




In an oven-dried 8 mL screwed-capped vial B₂Pin₂ (2.5 mg, 0.01 mmol, 10 mol%), 6,6'dibromo-2,2'-bipyridine (3.1 mg, 0.01 mmol, 10 mol%), **2** (47.4 mg, 0.15 mmol, 1.5 equiv.) were weighted. Then the vial was transferred into the glove-box, CuI (5.7 mg, 0.01 mmol, 30 mol%), **1a** (13.6 mg, 0.1 mmol, 1.0 equiv.) and anhydrous DCE (1 .0 mL) were added to the vial. The vial was sealed and moved outside of the glove-box. The vial was kept at 25 °C about 8 hours. After the reaction completion monitored by TLC ($R_f = 0.3$, PE), the reaction was quenched by brine (2 mL), and extracted with EtOAc (5 mL × 2), the organic solvent was filtrated through a pad of short anhrdrous Na₂SO₄ column. Evaporation and flash Silica gel column purification (petroleum as eluent) of the crude product provided **3a** (33.0 mg) in 73% isolated yield.

2-methyl-5-(trifluoromethyl)nona-3,4-dien-2-yl 2-iodobenzoate (3a)




Colourless oil. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.96 (d, *J* = 7.8 Hz, 1H), 7.69 (dd, *J* = 7.8, 1.8 Hz, 1H), 7.39 (t, *J* = 7.6 Hz, 1H), 7.13 (dt, *J* = 7.8, 1.8 Hz, 1H), 6.27–6.32 (m, 1H), 2.15–2.20 (m, 2H), 1.72 (s, 3H), 1.71 (s, 3H), 1.43–1.51 (m, 2H), 1.31–1.41 (m, 2H), 0.88 (t, *J* = 7.2 Hz, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 201.06 (q, *J* = 4.2 Hz), 165.64, 141.08, 136.48, 132.28, 130.64, 127.88, 123.58 (q, *J* = 259.5 Hz), 104.55, 102.67 (q, *J* = 33 Hz), 93.49, 80.60, 29.46, 27.48, 26.71, 26.05, 22.20, 13.73. ¹⁹**F NMR**

(376 MHz, CDCl₃) δ -64.16 (d, J = 3.3 Hz). IR (KBr, cm⁻¹): 3456, 1727, 1292, 1118, 741. HRMS-ESI(m/z): [M+Na]⁺ calcd. for C₁₈H₂₀F₃INaO₂, 475.0352; found, 475.0341.
2-methyl-5-(trifluoromethyl)deca-3,4-dien-2-yl 2-iodobenzoate (3b)



Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.96 (d, *J* = 7.8 Hz, 1H), 7.69 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.38 (t, *J* = 7.5 Hz, 1H), 7.13 (dt, *J* = 7.8, 1.5 Hz, 1H), 6.27–6.32 (m, 1H), 2.15–2.19 (m, 2H), 1.72 (s, 3H), 1.71 (s, 3H), 1.46–1.51 (m, 2H), 1.32–1.28 (m, 4H), 0.86 (t, *J* = 6.9 Hz, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 201.04 (q, *J* = 4.2 Hz), 165.62, 141.07, 136.46, 132.28, 130.64, 127.86, 123.62 (q, *J* = 272 Hz), 104.53, 102.68 (q, *J* = 33 Hz), 93.49, 80.58, 31.25, 27.46, 27.02, 26.70, 26.30, 22.32, 13.94. ¹⁹F NMR (376 MHz, CDCl₃) δ = -64.14 (d, *J* = 3.3 Hz). **IR** (KBr, cm⁻¹): 3422, 1726, 1637, 1292, 1118, 740. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₁₉H₂₂F₃INaO₂, 489.0509; found, 489.0500.


2-methyl-5-(trifluoromethyl)undeca-3,4-dien-2-yl 2-iodobenzoate (3c)



Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 7.96 (d, *J* = 7.8 Hz, 1H), 7.69 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.38 (t, *J* = 7.5 Hz, 1H), 7.12 (td, *J* = 7.8, 1.5 Hz, 1H), 6.29–6.31 (m, 1H), 2.15–2.19 (m, 2H), 1.72 (s, 3H), 1.71 (s, 3H), 1.49 (dt, *J* = 15.3, 7.8 Hz, 2H), 1.30–1.35 (m, 2H), 1.23–1.28 (m, 4H), 0.86 (t, *J* = 6.9 Hz, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 201.03 (q, *J* = 4.2 Hz), 165.58, 141.07, 136.41, 132.28, 130.65, 127.86, 123.61 (q, *J* = 273.6 Hz), 104.52 ,102.68 (q, *J* = 33.6 Hz), 93.51, 80.56, 31.49, 28.78, 27.44, 27.31, 26.70, 26.32, 22.53, 14.02. ¹⁹**F NMR** (376 MHz, CDCl₃) δ = -64.14 (d, *J* = 3.3 Hz). **IR**


(KBr, cm⁻¹): 3415, 2937, 1723, 1295, 1118, 743. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₂₀H₂₄F₃INaO₂, 503.0665; found, 503.0657.

2,7-dimethyl-5-(trifluoromethyl)octa-3,4-dien-2-yl 2-iodobenzoate (3d)



Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.96 (d, *J* = 7.8 Hz, 1H), 7.68 (d, *J* = 7.8 Hz, 1H), 7.38 (t, *J* = 7.5 Hz, 1H), 7.13 (t, *J* = 7.8 Hz, 1H), 6.26–6.30 (m, 1H), 2.01–2.12 (m, 2H), 1.79–1.86 (m, 1H), 1.72 (s, 6H), 0.95 (s, 3H), 0.93 (s, 3H). ¹³**C** NMR (150 MHz, CDCl₃) δ = 201.67 (q, *J* = 4.2 Hz), 165.67, 141.06, 136.50, 132.28, 130.60, 127.88, 123.65 (q, *J* = 273.6 Hz), 104.06, 101.38 (q, *J* = 33.6 Hz), 93.46, 80.65, 35.82, 27.53, 26.74, 26.73, 22.40, 22.38. ¹⁹**F** NMR (376 MHz, CDCl₃) δ = -63.92 (d, *J* = 3.3 Hz). **IR** (KBr, cm⁻¹): 3420, 1727, 1636, 1294, 1118, 742. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₁₈H₂₀F₃INaO₂, 475.0352; found, 475.0348.


5-(cyclopentylmethyl)-6,6,6-trifluoro-2-methylhexa-3,4-dien-2-yl 2 iodobenzoate (3e)



Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.96 (d, *J* = 7.8 Hz, 1H), 7.68 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.38 (t, *J* = 7.5 Hz, 1H), 7.13 (td, *J* = 7.8, 1.5 Hz, 1H), 6.30–6.36 (m, 1H), 2.53–2.58 (m, 1H), 1.87–1.98 (m, 2H), 1.71 (s, 6H), 1.66–1.71 (m, 2H), 1.56–1.61 (m, 2H), 1.43–1.49 (m, 2H), 1.27 (d, *J* = 18.4 Hz, 2H). ¹³C NMR (150 MHz, CDCl₃) δ = 200.11 (q, *J* = 4.2 Hz), 165.69, 141.05, 136.53, 132.27, 130.61, 127.88, 123.80 (q, *J* = 271 Hz), 106.95 (q, *J* = 31.5 Hz), 105.15, 93.47, 80.63, 37.28, 32.52, 32.27, 27.50, 26.64, 24.88, 24.81.¹⁹F NMR (376 MHz, CDCl₃) δ = -62.73 (d, *J* = 3.3 Hz). IR (KBr,


cm⁻¹): 3471, 1727, 1638, 1290, 1118, 741, 615. **HRMS-APCI**(m/z): [M+H]⁺ calcd. for C₂₀H₂₃F₃IO₂, 479.0689; found, 479.0688.

5-(cyclohexylmethyl)-6,6,6-trifluoro-2-methylhexa-3,4-dien-2-yl 2-iodobenzoate (3f)



Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.96 (d, *J* = 7.8 Hz, 1H), 7.70 (d, *J* = 7.8 Hz, 1H), 7.39 (t, *J* = 7.5 Hz, 1H), 7.13 (t, *J* = 7.8 Hz, 1H), 6.24–6.28 (m, 1H), 2.02–2.09 (m, 2H), 1.75–1.80 (m, 2H), 1.72 (s, 6H), 1.64–1.68 (m, 2H), 1.59–1.60 (m, 1H), 1.47–1.55 (m, 1H), 1.10–1.21 (m, 3H), 0.87–0.95 (m, 2H). ¹³C NMR (150 MHz, CDCl₃) δ = 201.54 (q, *J* = 4.2 Hz), 165.56, 141.09, 136.39, 132.29, 130.68, 127.86, 123.65 (q, *J* = 272.2 Hz), 103.99, 100.89 (q, *J* = 33 Hz), 93.54, 80.62, 36.00, 34.28, 33.12, 33.07, 27.52, 26.71, 26.34, 26.00. ¹⁹F NMR (376 MHz, CDCl₃) δ = -64.24 (d, *J* = 3.2 Hz). IR (KBr, cm⁻¹): 3417, 1722, 1627, 1293, 1116, 742, 613. HRMS-ESI(m/z): [M+Na]⁺ calcd. for C₂₁H₂₄F₃INaO₂, 515.0665; found, 515.0658.


2-methyl-7-phenyl-5-(trifluoromethyl)hepta-3,4-dien-2-yl 2-iodobenzoate (3g)



Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 7.95 (d, *J* = 7.8 Hz, 1H), 7.68 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.37 (t, *J* = 7.5 Hz, 1H), 7.25–7.29 (m, 2H), 7.17–7.20 (m, 3H), 7.12 (td, *J* = 7.8, 1.5 Hz, 1H), 6.24–6.27 (m, 1H), 2.82 (t, *J* = 8.1 Hz, 2H), 2.48–2.56 (m, 2H), 1.67 (s, 6H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 201.17 (q, *J* = 4.2 Hz), 165.61, 141.06, 140.53, 136.42, 132.31, 130.63, 128.43, 128.39, 127.89, 126.21, 123.51 (q, *J* = 271.5 Hz), 104.92, 101.89 (q, *J* = 33.0 Hz), 93.50, 80.44, 33.44, 27.98, 27.49, 26.52. ¹⁹**F NMR** (376 MHz, CDCl₃) δ = -63.98 (d, *J* = 3.2 Hz). **IR** (KBr, cm⁻¹): 3451, 1726,


1636, 1294, 1117, 742. **HRMS-ESI**(m/z): $[M+Na]^+$ calcd. for $C_{22}H_{20}F_3INaO_2$, 523.0352; found, 523.0350.

5-cyclopropyl-6,6,6-trifluoro-2-methylhexa-3,4-dien-2-yl 2-iodobenzoate (3h)




Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.95 (d, *J* = 7.8 Hz, 1H), 7.68 (d, *J* = 7.8 Hz, 1H), 7.39 (t, *J* = 7.5 Hz, 1H), 7.13 (t, *J* = 7.8 Hz, 1H), 6.29 (s, 1H), 1.68 (s, 6H), 1.35–1.41 (m, 1H), 0.82 (d, *J* = 8.1 Hz, 2H), 0.56–0.61(m, 1H), 0.52–0.54 (m, 1H). ¹³**C** NMR (150 MHz, CDCl₃) δ = 199.57 (q, *J* = 4.2 Hz), 165.70 ,141.02, 136.44, 132.31, 130.60, 127.90, 123.61 (q, *J* = 273 Hz), 106.11 (q, *J* = 34.5 Hz), 105.68, 93.45, 80.38, 27.61, 26.45, 7.16, 6.97, 6.53. ¹⁹**F** NMR (376 MHz, CDCl₃) δ = -63.87 (d, *J* = 3.3 Hz). **IR** (KBr, cm⁻¹): 3452, 1638, 1288, 1120, 741. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₁₇H₁₆INaO₂, 459.0039; found, 459.0033.

8-chloro-2-methyl-5-(trifluoromethyl)octa-3,4-dien-2-yl 2-iodobenzoate (3i)




Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 7.96 (d, *J* = 7.8 Hz, 1H), 7.69 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.39 (t, *J* = 7.5 Hz, 1H), 7.13 (td, *J* = 7.8, 1.5 Hz, 1H), 6.29–6.32 (m, 1H), 3.58 (dt, *J* = 6.3, 1.5 Hz, 2H), 2.36–2.39 (m, 2H), 2.00 (quint, *J* = 7.2 Hz, 2H), 1.72 (s, 6H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 200.87 (q, *J* = 4.2 Hz), 165.64, 141.08, 136.34, 132.36, 130.61, 127.92, 123.36 (q, *J* = 273 Hz), 105.28, 101.49 (q, *J* = 33.6 Hz), 93.47, 80.30, 43.92, 30.10, 27.70, 26.46, 23.73. ¹⁹**F NMR** (376 MHz, CDCl₃) δ = -64.19 (d, *J* = 3.2 Hz). **IR** (KBr, cm⁻¹): 3421, 2943, 1726, 1293, 1120, 743. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₁₇H₁₇F₃INaO₂, 494.9806; found, 494.9804.

5-((1,3-dioxoisoindolin-2-yl) methyl)-6,6,6-trifluoro-2-methylhexa-3,4-dien-2-yl 2iodobenzoate (3j)



Yellow oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.90 (d, *J* = 7.8 Hz, 1H), 7.80 (d, *J* = 5.4 Hz, 1H), 7.79 (d, *J* = 5.4 Hz, 1H), 7.64 (d, *J* = 5.4 Hz, 1H), 7.63 (d, *J* = 5.4 Hz, 1H), 7.54 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.33 (t, *J* = 7.5 Hz, 1H), 7.10 (td, *J* = 7.8, 1.5 Hz, 1H), 6.41 (dd, *J* = 6.3, 3.0 Hz, 1H), 4.55 (dd, *J* = 15.9, 3.0 Hz, 1H), 4.45 (dd, *J* = 15.9, 3.0 Hz, 1H), 1.63 (s, 3H), 1.55 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 200.33 (q, *J* = 4.2 Hz), 167.20, 165.15, 141.06, 135.79, 134.08, 132.33, 131.81, 130.83, 127.77, 123.42, 122.43 (q, *J* = 273 Hz), 107.42, 99.03 (q, *J* = 34.5 Hz), 93.66, 80.07, 34.10, 27.02, 26.24. ¹⁹F NMR (376 MHz, CDCl₃) δ = -63.13 (d, *J* = 3.1 Hz). IR (KBr, cm⁻¹): 3416, 1722, 1391, 1292, 1123, 734. HRMS-ESI(m/z): [M+Na]⁺ calcd. for C₂₃H₁₇F₃INaO₄, 578.0047; found, 578.0045.


6,6,6-trifluoro-2-methyl-5-(((4-methylphenyl)sulfonamido)methyl)hexa-3,4-dien-2-yl 2-iodobenzoate (3k)



Yellow oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 7.98 (d, *J* = 7.8 Hz, 1H), 7.76 (d, *J* = 7.5 Hz, 2H), 7.74 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.42 (t, *J* = 7.5 Hz, 1H), 7.27 (d, *J* = 7.5 Hz, 2H), 7.16 (td, *J* = 7.8, 1.5 Hz, 1H), 5.86 (dd, *J* = 6.6, 3.3 Hz, 1H), 5.61 (dd, *J* = 8.1, 3.9 Hz, 1H), 3.94 (ddd, *J* = 10.8, 8.1, 3.3 Hz, 1H), 3.78 (dt, *J* = 15.8, 3.6 Hz, 1H), 2.42 (s, 3H), 1.66 (s, 3H), 1.65 (s, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 200.63 (q, *J* = 4.2 Hz), 166.52, 143.65, 141.45, 137.52, 136.03, 132.97, 131.35, 129.89, 128.30, 127.44,


122.47 (q, J = 273 Hz), 106.80, 100.35 (q, J = 34.5 Hz), 93.84, 80.46, 39.54, 28.80, 25.53, 21.74. ¹⁹**F** NMR (376 MHz, CDCl₃) $\delta = -63.42$ (d, J = 3.0 Hz). **IR** (KBr, cm⁻¹): 3416, 1717, 1295, 1161, 744. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₂₂H₂₁F₃INaO₄, 602.0080; found, 602.0079.

5-(((tert-butoxycarbonyl)amino)methyl)-6,6,6-trifluoro-2-methylhexa-3,4-dien-2yl-2-iodobenzoate (3l)



Yellow oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.96 (d, *J* = 7.8 Hz, 1H), 7.71 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.39 (t, *J* = 7.5Hz, 1H), 7.14 (dd, *J* = 7.8, 1.5 Hz, 1H), 6.30 (dd, *J* = 6.3, 3.0 Hz, 1H), 5.13 (brs, 1H), 4.00–4.03 (m, 1H), 3.92 (ddd, *J* = 10.5, 5.1, 3.3 Hz, 1H), 1.73 (s, 3H), 1.71 (s, 3H), 1.40 (s, 9H). ¹³C NMR (150 MHz, CDCl₃) δ = 200.95 (q, *J* = 3.9 Hz), 166.05, 155.73, 141.30, 136.49, 132.64, 131.01, 128.12, 122.98 (q, *J* = 273 Hz), 106.24, 101.53 (q, *J* = 33.0 Hz), 93.71, 80.61, 79.92, 37.42, 28.51, 27.96, 26.48. ¹⁹F NMR (376 MHz, CDCl₃) δ = -63.19 (d, *J* = 2.3 Hz). IR (KBr, cm⁻¹): 3448, 1717, 1289, 1120, 742. HRMS-ESI(m/z): [M+Na]⁺ calcd. for C₂₀H₂₃F₃INaO₄, 548.0516; found, 548.0518.


(5-(benzamidomethyl)-6,6,6-trifluoro-2-methylhexa-3,4-dien-2-yl-2-iodobenzoate (3m)



Yellow oil. ¹**H NMR** (600 MHz, CDCl₃) *δ*= 7.95 (d, *J* = 7.8 Hz, 1H), 7.84 (d, *J* = 7.8 Hz, 2H), 7.58 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.40 (t, *J* = 7.5 Hz, 1H), 7.36 (t, *J* = 7.5 Hz, 1H), 7.29 (t, *J* = 7.8 Hz, 2H), 7.14 (td, *J* = 7.8, 1.5 Hz, 1H), 7.00 (brs, 1H), 6.17 (dd, *J*


= 6.0, 3.0 Hz, 1H), 4.52 (ddd, J = 16.1, 6.9, 3.3 Hz, 1H), 4.14 (dt, J = 16.1, 7.5 Hz, 1H), 1.71 (s, 3H), 1.69 (s, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 200.29 (q, J = 4.2 Hz), 167.35, 166.22, 141.15, 135.85, 133.87, 132.60, 131.46, 130.79, 128.38, 127.94, 127.21, 122.63 (q, J = 273.0 Hz), 106.11, 101.21 (q, J = 34.5 Hz), 93.58, 80.47, 35.87, 28.08, 26.20. ¹⁹**F NMR** (376 MHz, CDCl₃) δ = -63.19 (d, J = 2.3 Hz). **IR** (KBr, cm⁻¹): 3417, 1721, 1625, 1275, 1116, 615. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₂₂H₁₉F₃INaO₃, 552.0254; found, 552.0255.

7-hydroxy-2-methyl-5-(trifluoromethyl)hepta-3,4-dien-2-yl 2-iodobenzoate (3n)



Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.96 (d, *J* = 7.8 Hz, 1H), 7.71 (d, *J* = 7.2 Hz, 1H), 7.40 (t, *J* = 7.8 Hz, 1H), 7.15 (t, *J* = 7.2 Hz, 1H), 6.15–6.17 (m, 1H), 3.83–3.92 (m, 2H), 2.68 (brs, 1H), 2.41–2.54 (m, 2H), 1.74 (s, 3H), 1.68 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 200.63 (q, *J* = 4.2 Hz), 166.19, 141.17, 136.01, 132.60, 130.78, 127.98, 123.37 (q, *J* = 273.9 Hz), 105.13, 100.43 (q, *J* = 34.5 Hz), 93.64, 80.59, 59.66, 29.73, 28.84, 25.16. ¹⁹F NMR (376 MHz, CDCl₃) δ = -64.51 (d, *J* = 3.2 Hz). IR (KBr, cm⁻¹): 3420, 1638, 1293, 1118, 742. HRMS-ESI(m/z): [M+Na]⁺ calcd. for C₁₆H₁₆F₃INaO₃, 462.9988; found, 462.9992.


9-hydroxy-2-methyl-5-(trifluoromethyl)nona-3,4-dien-2-yl2-iodobenzoate (30)



Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 7.96 (d, *J* = 7.8 Hz, 1H), 7.69 (d, *J* = 7.5 Hz, 1H), 7.39 (t, *J* = 7.5 Hz, 1H), 7.13 (t, *J* = 7.8 Hz, 1H), 6.25 (dd, *J* = 6.3, 3.6 Hz, 1H), 3.60–3.66 (m, 2H), 2.18–2.19 (m, 2H), 1.71 (d, *J* = 8.7 Hz, 6H), 1.58–1.69 (m,


4H). ¹³**C NMR** (150 MHz, CDCl₃) δ =200.92 (q, *J* = 3.6 Hz), 165.75, 141.07, 136.39, 132.34, 130.63, 127.90, 123.51 (q, *J* = 273.0 Hz), 104.90, 102.58 (q, *J* = 33.3 Hz), 93.45, 80.54, 62.43, 32.06, 27.94, 26.24, 26.07, 23.63. ¹⁹**F NMR** (376 MHz, CDCl₃) δ = -63.90 (d, *J* = 3.3 Hz). **IR** (KBr, cm⁻¹): 3454, 1636, 1117, 742. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₁₈H₂₀F₃INaO₃, 491.0301; found, 491.0308.

7-((boraneyl-d-t)oxy)-2-methyl-5-(trifluoromethyl)hepta-3,4-dien-2-yl-2iodobenzoate (3p)



Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.95 (d, *J* = 7.8 Hz, 1H), 7.67 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.38 (t, *J* = 7.5 Hz, 1H), 7.12 (td, *J* = 7.8, 1.5 Hz, 1H), 6.28 (dd, *J* = 6.0, 3.0 Hz, 1H), 3.74 (t, *J* = 7.2 Hz, 2H), 2.40–2.43 (m, 2H), 1.71 (s, 6H), 0.87 (s, 9H), 0.04 (s, 3H), 0.03 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 201.51 (q, *J* = 4.2 Hz), 165.60, 141.06, 136.45, 132.29, 130.65, 127.87, 123.53 (q, *J* = 273.6 Hz), 104.41, 99.16 (q, *J* = 34.5 Hz), 93.50, 80.43, 60.97, 29.98, 27.47, 26.58, 25.85, 18.22, -5.35, -5.36. ¹⁹F NMR (376 MHz, CDCl₃) δ = -64.11 (d, *J* = 3.3 Hz), -64.17 (d, *J* = 3.2 Hz). **IR** (KBr, cm⁻¹): 3420, 2933, 1728, 1466, 1292, 1118, 840, 742. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₂₂H₃₀F₃INaO₃Si, 577.0853; found, 577.0853.


2-methyl-5-(trifluoromethyl)-7-((triisopropylsilyl)oxy)hepta-3,4-dien-2-yl-2iodobenzoate (3q)



Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 7.96 (d, *J* = 7.8 Hz, 1H), 7.69 (d, *J* = 7.5 Hz, 1H), 7.38 (t, *J* = 7.5 Hz, 1H), 7.13 (t, *J* = 7.8 Hz, 1H), 6.28 (dd, *J* = 6.3, 3.3 Hz,


1H), 3.81 (t, J = 7.2 Hz, 2H), 2.40–2.51 (m, 2H), 1.71 (s, 6H), 1.03 (s, 18H), 0.97–1.12 (m, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 201.45 (q, J = 4.2 Hz), 165.54, 141.09, 136.37, 132.30, 130.69, 127.86, 123.45 (q, J = 273.6 Hz), 104.38, 99.15 (q, J = 34.5 Hz), 93.53, 80.41, 61.34, 30.03, 27.44, 26.60, 17.94, 11.93. ¹⁹F NMR (376 MHz, CDCl₃) δ = -64.14 (d, J = 3.3 Hz). IR (KBr, cm⁻¹): 3416, 1623, 1115, 611. HRMS-ESI(m/z): [M+Na]⁺ calcd. for C₂₅H₃₉F₃INaO₃Si, 619.1323; found, 619.1325.

2-methyl-7-((tetrahydro-2H-pyran-2-yl)oxy)-5-(trifluoromethyl)hepta-3,4-dien-2yl 2-iodobenzoate (3r)




3r, dr = 1:1

Colourless oil, mixture of isomer (1:1). ¹**H** NMR (600 MHz, CDCl₃) δ = 7.95 (d, *J* = 7.5 Hz, 1H), 7.68 (dt, *J* = 7.8, 1.8 Hz, 1H), 7.38 (t, *J* = 7.5 Hz, 1H), 7.12 (td, *J* = 7.8, 1.5 Hz, 1H), 6.31–6.33 (m, 1H), 4.58 (t, *J* = 3.9 Hz, 1H), 3.85–3.88 (m, 1H), 3.81–3.84 (m, 1H), 3.54–3.58 (m, 1H), 3.45–3.49 (m, 1H), 2.49–2.53 (m, 2H), 1.75–1.83 (m, 1H), 1.72 (s, 6H), 1.65–1.68 (m, 1H), 1.51–1.58 (m, 2H), 1.46–1.49 (m, 2H). ¹³C NMR (150 MHz, CDCl₃) δ = 201.55 (q, *J* = 4.2 Hz), 165.69, 141.03, 136.52, 132.27, 130.63, 127.87, 123.43 (q, *J* = 273.6 Hz), 104.64, 99.55 (q, *J* = 15.0 Hz), 98.93, 93.46, 80.53, 64.81, 62.36, 30.62, 27.39, 27.08, 26.58, 25.40, 19.52. ¹⁹F NMR (376 MHz, CDCl₃) δ = -64.08 (d, *J* = 3.3 Hz), -64.17 (d, *J* = 3.2 Hz). IR (KBr, cm⁻¹): 3418, 1725, 1626, 1293, 1119, 743. HRMS-ESI(m/z): [M+Na]⁺ calcd. for C₂₁H₂₄F₃INaO₄, 547.0564; found, 547.0566. **2-methyl-7-(pivaloyloxy)-5-(trifluoromethyl)hepta-3,4-dien-2-yl-2-iodobenzoate** (3s)




Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.95 (d, *J* = 7.8 Hz, 1H), 7.68 (d, *J* = 7.5 Hz, 1H), 7.40 (t, *J* = 7.5 Hz, 1H), 7.14 (t, *J* = 7.8 Hz, 1H), 6.33–6.36 (m, 1H), 4.17–4.26 (m, 2H), 2.52–2.56 (m, 2H), 1.72 (s, 6H), 1.18 (s, 9H). ¹³**C** NMR (150 MHz, CDCl₃) δ = 201.24 (q, *J* = 4.2 Hz), 178.28, 165.71, 141.01, 136.33, 132.35, 130.64, 127.91, 123.19 (q, *J* = 273.0 Hz), 105.25, 98.95 (q, *J* = 34.5 Hz), 93.45, 80.22, 61.58, 38.67, 27.52, 27.11, 26.52, 25.89. ¹⁹**F** NMR (376 MHz, CDCl₃) δ = -64.25 (d, *J* = 3.3 Hz). **IR** (KBr, cm⁻¹): 3450, 1727, 1636, 1119. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₂₁H₂₄F₃INaO₄, 547.0564; found, 547.0567.

2-methyl-7-(tosyloxy)-5-(trifluoromethyl)hepta-3,4-dien-2-yl-2-iodobenzoate (3t)




Colourless oil. ¹H NMR (400 MHz, CDCl₃) δ = 7.96 (dd, J = 7.8, 1.2 Hz, 1H), 7.77 (d, J = 8.4 Hz, 2H), 7.68 (dd, J = 7.8, 1.5 Hz, 1H), 7.40 (dd, J = 7.8, 1.2 Hz, 1H), 7.31 (d, J = 8.4 Hz, 2H), 7.14 (dt, J = 7.8, 1.5 Hz, 1H), 6.27 (dd, J = 6.3, 3.1 Hz, 1H), 4.20 (t, J = 6.6 Hz, 2H), 2.54–2.59 (m, 2H), 2.42 (s, 3H), 1.69 (s, 3H), 1.68 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 201.28 (q, J = 4.2 Hz), 165.62, 144.95, 141.05, 136.25, 132.79, 132.42, 130.69, 129.90, 127.96, 127.95, 122.97 (q, J = 273.6 Hz), 105.59, 97.67 (q, J = 35.4 Hz), 93.50, 80.12, 66.95, 27.56, 26.38, 26.31, 21.65. ¹⁹F NMR (376 MHz, CDCl₃) δ = -64.23 (d, J = 3.1 Hz). IR (KBr, cm⁻¹): 3452, 1637, 1119, 745. HRMS-ESI(m/z): [M+Na]⁺ calcd. for C₂₃H₂₂F₃INaO₅S, 617.0077; found, 617.0075.

7-(benzoyloxy)-2-methyl-5-(trifluoromethyl)hepta-3,4-dien-2-yl-2-iodobenzoate (3u)




S24

Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.99–8.01 (m, 2H), 7.93 (d, *J* = 7.8 Hz, 1H), 7.65 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.55 (t, *J* = 7.5 Hz, 1H), 7.41 (t, *J* = 7.8 Hz, 2H), 7.37 (t, *J* = 7.5, 1.2 Hz, 1H), 7.11 (dt, *J* = 7.8, 1.5 Hz, 1H), 6.34 (dd, *J* = 6.3, 3.0 Hz, 1H), 4.49 (td, *J* = 6.6, 2.4 Hz, 2H), 2.66–2.74 (m, 2H), 1.69 (s, 3H), 1.68 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 201.43 (q, *J* = 4.2 Hz), 166.30, 165.68, 141.02, 136.42, 133.05, 132.30, 130.63, 129.94, 129.61, 128.37, 127.89, 123.29 (q, *J* = 273.6 Hz), 105.36, 98.97 (q, *J* = 34.8 Hz), 93.45, 80.24, 62.20, 27.48, 26.48, 26.09.¹⁹F NMR (376 MHz, CDCl₃) δ = -64.19 (d, *J* = 3.1 Hz). IR (KBr, cm⁻¹): 3420, 1722, 1633, 1275, 1117, 711. HRMS-ESI(m/z): [M+Na]⁺ calcd. for C₂₃H₂₀F₃INaO₄, 567.0251; found, 567.0255. **1-(3-(trifluoromethyl) hepta-1,2-dien-1-yl)cyclohexyl-2-iodobenzoate (3v)**




Colourless oil. ¹H NMR (600 MHz, CDCl₃) δ = 7.97 (d, *J* = 7.8 Hz, 1H), 7.74 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.39 (t, *J* = 7.5 Hz, 1H), 7.13 (td, *J* = 7.8, 1.5 Hz, 1H), 6.29–6.32 (m, 1H), 2.30–2.36 (m, 2H), 2.14–2.18 (m, 2H), 1.76–1.81 (m, 2H), 1.63–1.67 (m, 2H), 1.57–1.62 (m, 3H), 1.43–1.47 (m, 2H), 1.32–1.37 (m, 3H), 0.86 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 201.83 (q, *J* = 4.2 Hz), 165.31, 141.24, 136.25, 132.31, 130.65, 127.88, 123.72 (q, *J* = 271.5 Hz), 103.64, 102.41 (q, *J* = 33.3 Hz), 93.68, 82.25, 35.83, 35.02, 29.49, 26.09, 25.15, 22.23, 22.14, 22.06, 13.72. ¹⁹F NMR (376 MHz, CDCl₃) δ = -63.89 (d, *J* = 3.3 Hz). IR (KBr, cm⁻¹): 3460, 2935, 1726, 1292, 1120, 741. HRMS-ESI(m/z): [M+Na]⁺ calcd. for C₂₁H₂₄F₃INaO₂, 515.0665; found, 515.0666. tert-butyl-4-((2-iodobenzoyl)oxy)-4-(3-(trifluoromethyl)hepta-1,2-dien-1-yl)piperidine-1-carboxylate (3w)



Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 7.98 (dd, *J* = 7.8, 0.6 Hz, 1H), 7.71 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.40 (td, *J* = 7.8, 0.9 Hz, 1H), 7.15 (td, *J* = 7.8, 1.5 Hz, 1H), 6.31– 6.34 (m, 1H), 3.67–3.85 (m, 2H), 3.31–3.36 (m, 2H), 2.32–2.44 (m, 2H), 2.12–2.21 (m, 2H), 1.83–1.97 (m, 2H), 1.42–1.48 (m, 2H), 1.46 (s, 9H), 1.30–1.39 (m, 2H), 0.86 (t, *J* = 7.2 Hz, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 201.84 (q, *J* = 5.1 Hz), 165.26, 154.70, 141.29, 135.76, 132.58, 130.64, 127.94, 123.48 (q, *J* = 274.4 Hz), 103.38, 103.26 (q, *J* = 34.5 Hz), 103.15, 102.53, 93.60, 79.85, 35.12, 34.36, 29.41, 28.38, 26.01, 22.17, 13.66. ¹⁹**F NMR** (376 MHz, CDCl₃) δ = -63.92 (d, *J* = 3.1 Hz). **IR** (KBr, cm⁻¹): 3466, 1729, 1697, 1423, 1289, 1123, 741. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₂₅H₃₁F₃INaO₂, 616.1142; found, 616.1134.

3-methyl-1-phenyl-6-(trifluoromethyl)deca-4,5-dien-3-yl-2-iodobenzoate (3x)




3x, dr = 1:1

Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) isomer δ = 7.97 (d, *J* = 7.8 Hz, 1H×2), 7.68–7.70 (m, 1H×2), 7.38 (td, J = 7.5 2.4 Hz, 1H×2), 7.27 (t, J = 7.5 Hz, 2H×2), 7.20 (d, J = 8.1 Hz, 2H×2), 7.18 (t, J = 7.2 Hz, 1H×2), 7.13 (d, J = 7.5 Hz, 1H×2), 6.22–6.24 (m, 1H×2), 2.76 (t, J = 8.7 Hz, 2H×2), 2.32–2.38 (m, 2H×2), 2.17–2.21 (m, 2H×2), 1.77 (d, J = 7.8 Hz, 3H×2), 1.51 (t, J = 7.5 Hz, 1H×2), 1.46 (t, J = 7.5 Hz, 1H×2), 1.33–1.39 (m,2H×2), 0.84–0.90 (m, 3H×2). ¹³C NMR (150 MHz, CDCl₃) δ = 201.13 (q, *J* = 4.2 Hz), 201.07 (q, *J* = 4.2 Hz), 165.48, 165.35, 141.34, 141.32, 141.19, 141.14, 136.30, 136.09, 132.41, 132.37, 130.73, 130.65, 128.47 (C×2), 128.38, 128.36, 127.89 (C×2),

126.02 (C×2), 123.67 (q, J = 271.8 Hz), 123.65 (q, J = 271.8 Hz), 103.87, 103.85, 102.76 (q, J = 33.0 Hz), 102.74 (q, J = 33.0 Hz), 93.64, 93.57, 82.82, 82.72, 42.30, 41.58, 30.35, 30.32, 29.49, 29.48, 26.15, 26.13, 24.82, 24.16, 22.21, 22.17, 13.73, 13.69. **IR** (KBr, cm⁻¹): 3422, 1727, 1631, 1290, 1121, 741. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₂₅H₂₆F₃INaO₂, 565.0822; found, 565.0816.


5-((4-((10S,13R,14S)-3-(benzoyloxy)-10,13-dimethylhexadecahydro-1Hcyclopenta[a]phenanthren-17-yl) pentanamido)methyl)-6,6,6-trifluoro-2methylhexa-3,4-dien-2-yl-2-iodobenzoate (3y)




3y, dr = 1:1

White foam. ¹**H** NMR (600 MHz, CDCl₃) δ = 8.05 (d, *J* = 6.9 Hz, 2H), 7.99 (d, *J* = 6.9 Hz, 1H), 7.71 (d, *J* = 7.2 Hz, 1H), 7.53 (d, *J* = 6.9 Hz, 1H), 7.41–7.44 (m, 3H), 7.18 (t, *J* = 7.2 Hz, 1H), 6.46 (s, 1H), 6.15 (s, 1H), 4.31 (d, *J* = 12 Hz, 1H), 3.96 (d, *J* = 14.1 Hz, 1H), 3.61–3.67 (m, 1H), 2.27–2.38 (m, 1H), 2.13–2.22 (m, 1H), 1.94–2.22 (m, 1H), 1.81–1.91 (m, 6H), 1.72 (s, 3H), 1.69 (s, 3H), 1.45–1.60 (m, 4H), 1.31–1.43 (m, 6H), 1.16–1.30 (m, 2H), 1.02–1.15 (m, 4H), 0.95 (s, 6H), 0.83 (t, *J* = 5.4 Hz, 3H), 0.58 (d, *J* = 5.2 Hz, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 199.63 (q, *J* = 3.3 Hz, C×2), 174.06, 174.01, 166.26 (C×2), 166.11(C×2), 141.22 (C×2), 135.98 (C×2), 132.67 (C×2), 130.92 (C×2), 130.73 (C×2), 129.48 (C×2), 128.24 (C×2), 128.02 (C×2), 122.48 (q, *J* = 273.6 Hz, C×2), 106.72 (C×2), 101.42 (q, *J* = 34.2 Hz, C×2), 93.56 (C×2), 80.38 (C×2), 74.99 (C×2), 56.40, 56.37, 55.89, 55.76, 42.67, 42.66, 41.95, 40.45, 40.44, 40.07, 35.77, 35.54, 35.47, 35.37, 35.07, 34.63, 33.16, 32.99, 32.38, 31.73, 31.70, 28.90, 28.86, 28.15, 27.04, 26.78, 26.31, 25.04, 24.97, 24.15, 23.33, 20.84, 18.33, 12.01. ¹⁹F NMR (376 MHz, DMSO) δ = -61.72 (d, *J* = 3.4 Hz), -61.75 (d, *J* = 3.4 Hz). **IR** (KBr,

cm⁻¹): 3415, 2936, 1716, 1654, 1278, 1118, 712. HRMS-ESI(m/z): [M+Na]⁺ calcd. for C₄₆H₅₇F₃INaO₄, 910.3126; found, 910.3143.




Late-stage functionalization of allene compounds



3t


A 8 mL vial was charged with 3t (30.4 mg, 0.05 mmol, 1 equiv.), LiBr (18.0 mg, 4 equiv.) and THF (0.5 mL). The vial was sealed with a PTFE lined cap and heated to reflux for 72 hours. Then cool to room temperature. The solvent was removed in vacuo and the residue was further purified with flash column chromatography (PE: DCM: EA = 30: 3: 1) to give the titled compound **6a** as colorless oil (23.1 mg, 92%).¹H NMR (600 MHz, CDCl₃) δ = 7.96 (d, J = 7.8 Hz, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.40 (t, J = 7.5 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 6.35–6.37 (m, 1H), 3.51 (t, J = 7.2 Hz, 2H), 2.69– 2.85 (m, 2H), 1.74 (s, 3H), 1.73 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 201.25 (q, J

= 4.2 Hz), 165.68, 141.07, 136.21, 132.41, 130.63, 127.92, 123.05 (q, J = 273.6 Hz), 105.82, 100.16 (q, J = 33.6 Hz), 93.52, 80.18, 29.94, 28.60, 27.73, 26.44. ¹⁹F NMR (376 MHz, CDCl₃) δ = -64.27 (d, J = 3.3 Hz). **IR** (KBr, cm⁻¹): 3415, 1622, 1399, 1118, 617. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₁₆H₁₅BrF₃INaO₂, 524.9144; found, 524.9157.



A 8 mL vial was charged with **3t** (30.4 mg, 0.05 mmol, 1 equiv.) and PhSNa (20.1 mg, 0.15 mmol, 3 equiv.) in EtOH 1mL. The reaction was stirred at 45 °C for another 16 hours. The vial was allowed to cool to room temperature. The solvent was then removed in vacuo and the residue was further purified with flash column chromatography (hexane: ethyl acetate: DCM = 10: 1: 3) to give the titled compound **6b** as colorless oil (25.8 mg, 97%). ¹**H NMR** (600 MHz, CDCl₃) δ = 7.96 (d, *J* = 7.9 Hz, 1H), 7.68 (d, *J* = 7.7 Hz, 1H), 7.38 (t, *J* = 7.5 Hz, 1H), 7.34 (d, *J* = 7.6 Hz, 2H), 7.27 (d, *J* = 7.7 Hz, 2H), 7.18 (t, *J* = 7.2 Hz, 1H), 7.13 (t, *J* = 7.6 Hz, 1H), 6.33 (d, *J* = 2.6 Hz, 1H), 3.08 (t, *J* = 7.6 Hz, 2H), 2.51 (dd, *J* = 14.5, 7.0 Hz, 2H), 1.73 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ = 201.11 (q, *J* = 3.5 Hz), 165.63, 141.07, 138.29, 132.36, 130.85, 129.57, 129.01, 127.90, 128.30, 124.59 (q, *J* = 544.2 Hz), 105.53, 101.08 (q, *J* = 34.6 Hz), 99.96, 93.55, 80.30, 31.35, 29.69, 27.75, 26.44. ¹⁹F NMR (376 MHz, CDCl₃) δ = -64.07 (d, *J* = 3.3 Hz). **IR** (KBr, cm⁻¹): 3419, 1725, 1635, 1293, 1116, 743. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₂₂H₂₀F₃INaO₂, 555.0073; found, 555.0090.


7-iodo-2-methyl-5-(trifluoromethyl)hepta-3,4-dien-2-yl-2-iodobenzoate (6c)



A 8 mL vial was charged with **3t** (30.4 mg, 0.05 mmol, 1equiv.), NaI (30 mg, 4 equiv.) and acetone (1 mL). The vial was sealed with a PTFE lined cap and heated to reflux for

18 hours. Then cool to room temperature. The solvent was then removed in vacuo and the residue was further purified with flash column chromatography (PE: DCM: EA = 30: 3: 1) to give the titled compound **6c** as yellowish oil (26.9 mg, 98%). ¹H NMR (400 MHz, CDCl₃) δ = 7.96 (d, *J* = 7.8 Hz, 1H), 7.69 (d, *J* = 7.8 Hz, 1H), 7.40 (t, *J* = 7.5 Hz, 1H), 7.14 (t, *J* = 7.5 Hz, 1H), 6.35 (s, 1H), 3.21–3.34 (m, 2H), 2.65–2.91 (m, 2H), 1.74 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ = 201.16 (q, *J*=4.1 Hz), 165.66, 141.08, 136.23, 132.40, 130.63, 127.93, 121.11 (q, *J* = 445.8 Hz), 106.08, 101.94 (q, *J* = 34.8 Hz), 93.55, 80.13, 30.76, 29.69, 27.81, 26.47. ¹⁹F NMR (376 MHz, CDCl₃) δ = -64.01 (s). IR (KBr, cm⁻¹): 3418, 1724, 1629, 1291, 1117, 742. HRMS-ESI(m/z): [M+Na]⁺ calcd. for C₁₆H₁₅F₃I₂NaO₂, 572.9006; found, 572.9023.


2-methyl-7-((5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl) pentanoyl)oxy)-5-(trifluoromethyl)hepta-3,4-dien-2-yl-2-iodobenzoate (6d)



Biotin was treated with 1 M NaOH aqueous until dissolution, then solvent was then removed in vacuo to afford 4. A 8 mL vial was charged with **3t** (15.2 mg, 0.025 mmol, 1 equiv.), **4** (13.4 mg, 2 equiv.) and DMF (0.5 mL). The vial was sealed with a PTFE lined cap and heated to 100 °C for 4 hours. The vial was allowed to cool to room temperature. The solvent was then removed in vacuo and the residue was further purified with flash column chromatography (DCM: CH₃OH = 50: 1) to give the titled compound as colorless oil (17.4 mg, 57%). ¹**H** NMR (400 MHz, CDCl₃) δ = 7.95 (d, *J* = 7.9 Hz, 1H), 7.68 (d, J = 7.7 Hz, 1H), 7.40 (t, *J* = 7.5 Hz, 1H), 7.14 (t, *J* = 7.6 Hz, 1H), 6.35 (s, 1H), 5.78 (s, 1H), 5.40 (s, 1H), 4.49 (s, 1H), 4.16–4.34 (m, 3H), 3.14 (s, 1H), 2.85–2.95 (m, 1H), 2.72 (d, *J* = 12.8 Hz, 1H), 2.55 (s, 2H), 2.30 (t, *J* = 7.2 Hz, 2H), 1.72 (s, 6H), 1.66 (dd, *J* = 19.3, 7.5 Hz, 4H), 1.42 (d, *J* = 6.0 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ = 201.27 (q, *J* = 4.1 Hz), 173.30, 165.73, 163.50, 140.98, 136.37, 132.37, 130.60, 127.94, 123.18 (q, *J* = 273.6 Hz), 105.20, 98.82 (q, *J* = 34.5 Hz), 93.43,


80.23, 61.91, 61.46, 60.06, 55.34, 40.52, 33.71, 28.31, 28.22, 27.54, 26.43, 25.92, 24.64. ¹⁹F NMR (376 MHz, CDCl₃) δ = -64.20 (d, *J* = 10.4 Hz). **IR** (KBr, cm⁻¹): 3420, 1640, 1293, 1118, 744. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₂₆H₃₀F₃IN₂NaO₅S, 689.0764; found, 689.0756.

Palladium-catalysed suzuki coupling




Allenes (0.1 mmol, 1.0 equiv.), $Pd(PPh_3)_4$ (4.00 mg, 0.003 mmol, 3 mol%) and arylphenylboric acid (1.25 mmol, 1.25 equiv.), then 2M Na₂CO₃ (0.1mL) was added to toluene (1 mL), and stirred at 120 °C for 12 h under nitrogen atmosphere. The reaction was cooled to room temperature and extracted with ethyl acetate and water. The organic phase was dried and dried and purified by column chromatography.

2-methyl-5-(trifluoromethyl)nona-3,4-dien-2-yl-4'-bromo-[1,1'-biphenyl]-2carboxylate (7a)




Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.82 (dd, *J* = 7.8, 0.9 Hz, 1H), 7.49– 7.55 (m, 3H), 7.42 (td, *J* = 7.5, 0.9 Hz, 1H), 7.28–7.31 (m, 1H), 7.18 (d, *J* = 8.4 Hz, 2H), 6.03–6.09 (m, 1H), 2.14 (dd, *J* = 10.5, 4.8 Hz, 2H), 1.42 (dt, *J* = 15.2, 7.5 Hz, 2H), 1.38 (s, 3H), 1.33–1.37 (m, 5H), 0.89 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 200.78 (q, *J* = 4.5 Hz), 167.02, 141.14, 140.72, 131.61, 131.21, 131.07, 130.49, 130.22, 130.04, 127.53, 123.59 (q, *J* = 273.8 Hz), 121.27, 104.23, 102.35 (q, *J* = 33.4 Hz), 79.54, 29.38, 26.99, 26.20, 25.99, 22.16, 13.70. ¹⁹F NMR (376 MHz, CDCl₃) δ = -64.11 (s). **IR** (KBr, cm⁻¹): 3416, 1719, 1289, 1118, 759. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₂₄H₂₄BrF₃NaO₂, 503.0804; found, 503.0794. 2-methyl-5-(trifluoromethyl)nona-3,4-dien-2-yl-3'-hydroxy-[1,1'-biphenyl]-2carboxylate (7b)



Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.75 (dd, *J* = 7.8, 0.9 Hz, 1H), 7.48 (td, *J* = 7.5, 1.2 Hz, 1H), 7.39 (td, *J* = 7.5, 1.2 Hz, 1H), 7.32 (d, *J* = 7.5 Hz, 1H), 7.24 (d, *J* = 7.8 Hz, 1H), 6.86 (d, *J* = 7.5 Hz, 1H), 6.83 (dd, *J* = 7.8, 2.1 Hz, 1H), 6.75–6.78 (m, 1H), 5.97 (dt, *J* = 6.4, 3.3 Hz, 1H), 5.41 (brs, 1H), 2.10–2.14 (m, 2H), 1.70 (brs, 1H), 1.38–1.45 (m, 2H), 1.32–1.37 (m, 1H), 1.35 (s, 3H), 1.31 (s, 3H), 0.88 (t, *J* = 7.3 Hz, 3H). ¹³**C** NMR (150 MHz, CDCl₃) δ = 200.71 (q, *J* = 4.2 Hz), 167.90, 155.42, 143.20, 141.75, 132.01, 130.97, 130.33, 129.59, 129.26, 127.27, 123.62 (q, *J* = 273.8 Hz), 121.07, 115.67, 114.11, 104.39, 102.29 (q, *J* = 33.6 Hz), 79.58, 29.40, 26.91, 26.06, 26.01, 22.15, 13.68. ¹⁹**F** NMR (376 MHz, CDCl₃) δ = -64.12 (d, *J* = 3.2 Hz). **IR** (KBr, cm⁻¹): 3415, 1695, 1596, 1296, 1119, 759. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₂₄H₂₅F₃NaO₃, 441.1648; found, 441.1649.


2-methyl-5-(trifluoromethyl)nona-3,4-dien-2-yl 2-(thiophen-3-yl)benzoate (7c)



Colourless oil. ¹**H NMR** (400 MHz, CDCl₃) δ = 7.74 (d, *J* = 7.5 Hz, 1H), 7.48 (t, *J* = 7.5 Hz, 1H), 7.38 (t, *J* = 7.5 Hz, 2H), 7.33 (d, *J* = 2.5 Hz, 1H), 7.21 (s, 1H), 7.08 (d, *J* = 4.8 Hz, 1H), 6.03–6.09 (m, 1H), 2.10–2.17 (m, 2H), 1.39–1.45 (m, 5H), 1.39 (s, 3H), 1.34–1.38 (m, 2H), 0.89 (t, *J* = 7.2 Hz, 3H). ¹³**C NMR** (100 MHz, CDCl₃) δ = 200.80 (q, *J* = 3.3 Hz), 167.59, 141.82, 136.66, 132.24, 130.98, 130.59, 129.59, 128.90, 127.31, 123.65 (q, *J* = 272.7 Hz), 124.90, 122.18, 104.39,102.30 (q, *J* = 33.5 Hz), 79.47, 29.44,


27.07, 26.21, 26.03, 22.20, 13.74. ¹⁹**F** NMR (376 MHz, CDCl₃) δ = -64.04 (s). **IR** (KBr, cm⁻¹): 3411, 1619, 1292, 1117, 753. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₂₂H₂₃F₃NaO₂S, 431.1253; found, 431.1263.

Synthesis of CF₃-substituted allenol via hydrolysis of compound 3a




Potassium carbonate (34.6 mg, 0.25 mmol) was added to a solution of **3a** (45.2 mg, 0.1 mmol) in CH₃OH (2 mL). The solution was stirred for about 12 h at 40 °C. After **3a** complete reaction, the reaction was quenched by brine (2 mL), and extracted with EtOAc (5 mL × 2), the organic solvent was filtrated through a pad of short anhrdrous Na₂SO₄ column. Evaporation and flash Silica gel column purification (petroleum: EA = 10:1 as eluent) of the crude product provided **5a** (13.2 mg) in 60% isolated yield.

2-methyl-5-(trifluoromethyl)nona-3,4-dien-2-ol (5a)




Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.79–5.82 (m, 1H), 2.13– 2.18 (m, 2H), 1.84 (s, 1H), 1.44 (dd, *J* = 15.2, 7.5 Hz, 2H), 1.38 (s, 6H), 0.92 (t, *J* = 7.2 Hz, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 199.44 (q, *J* = 4.2 Hz), 123.69 (q, *J* = 271.5 Hz), 108.05, 102.21 (q, *J* = 33.6 Hz), 69.97, 29.72, 29.63, 29.31, 25.97, 22.14, 13.71. **IR** (KBr, cm⁻ ¹): 3416, 1621, 1118, 617. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₁₁H₁₇NaO, 245.1124; found, 245.1121.

7-((tert-butyldimethylsilyl)oxy)-2-methyl-5-(trifluoromethyl)hepta-3,4-dien-2-ol (5p)



Colourless oil. ¹**H NMR** (400 MHz, CDCl₃) δ = 5.80–5.85 (m, 1H), 3.78 (t, *J* = 6.4 Hz, 2H), 2.37 (td, *J* = 6.4, 2.8 Hz), 1.38 (s, 6H), 0.90 (s, 9H), 0.08 (s, 6H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 199.85 (q, *J* = 4.2 Hz), 123.48 (q, *J* = 273.0 Hz), 108.43, 98.96 (q, *J* = 34.2 Hz), 69.66, 60.77, 30.12, 29.92, 29.54, 18.38, 15.33, -5.22, -5.33. **IR** (KBr, cm-1): 3445, 1634, 1117, 690. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₁₅H₂₇F₃KO₂Si, 363.1364; found 363.1388.


tert-butyl-4-hydroxy-4-(3-(trifluoromethyl)hepta-1,2-dien-1-yl)piperidine-1carboxylate (5w)





Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.75–5.78 (m, 1H), 3.76 (t, *J* = 6.4 Hz, 2H), 3.28 (td, *J* = 6.4, 2.8 Hz), 2.11–2.22 (m, 2H), 1.64–1.66 (m, 4H), 1.38 (s, 6H), 1.46 (s, 9H), 1.43 (dd, *J* = 15.6, 7.8 Hz, 3H), 1.38 (dd, *J* = 15.0, 7.2 Hz, 2H), 0.92 (t, *J* = 7.2 Hz, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 200.03 (q, *J* = 3.9 Hz), 154.75, 123.52 (q, *J* = 273.6 Hz), 106.84, 103.08 (q, *J* = 30.0 Hz), 79.63, 69.28, 37.08, 29.49, 28.41, 25.94, 23.14, 13.73. **IR** (KBr, cm-1): 3451, 1638, 689. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₁₈H₂₉F₃NO₃, 364.20941; found 364.20947.


6-methyl-3-(trifluoromethyl)hepta-3,4-diene-1,6-diol (5s)




Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 5.81–5.84 (m, 1H), 3.80 (t, *J* = 5.4 Hz, 2H), 2.42 (td, *J* = 5.4, 2.8 Hz), 1.43 (s, 3H), 1.40 (s, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 199.93 (q, *J* = 4.2 Hz), 123.43 (q, *J* = 273.3 Hz), 108.37, 98.15 (q, *J* = 34.2 Hz), 69.99, 59.55, 30.16, 30.13, 29.84. **IR** (KBr, cm-1): 3459, 1368, 694. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₉H₁₃F₃NaO₂, 233.07599; found 233.07607.

6-hydroxy-6-methyl-3-(trifluoromethyl)hepta-3,4-dien-1-yl


methylbenzenesulfonate (5t)



Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.79 (d, *J* = 8.4 Hz, 2H), 7.36 (d, *J* = 8.1 Hz, 2H), 5.88–5.92 (m, 1H), 4.18 (ddt, *J* = 21.9, 10.2, 6.0 Hz, 2H), 2.51–2.56 (m, 2H), 2.46 (s, 3H), 1.40 (s, 6H). ¹³C NMR (150 MHz, CDCl₃) δ = 200.09 (q, *J* = 3.9 Hz), 145.19, 132.63, 129.96, 127.92, 123.12 (q, *J* = 273.0 Hz), 109.41, 97.18 (q, *J* = 34.5 Hz), 69.76, 66.97, 29.78, 29.17, 26.21, 21.65. **IR** (KBr, cm-1): 3458, 2980, 2378, 1647, 661, 558. **HRMS-ESI**(m/z): [M+Na]⁺ calcd. for C₁₆H₁₉F₃NaO₄S, 387.08484; found 387.08442.




NOESY Experiment:



NOESY Experiments demonstrated E selectivity is the major product

Construction of trifluoromethyl substituted 1,3-dienes



Allenes (0.1 mmol, 1.0 equiv.), Pd(PPh₃)₄ (4.00 mg, 0.003 mmol, 3.0 mol%) and arylphenylboric acid (0.175 mmol, 1.75 equiv.), then 2 M Na₂CO₃ (0.1 mL), EtOH (70.0 μ L) were added to toluene (1.0 mL), and stirred at 100 °C for 10 h under nitrogen atmosphere. The reaction was cooled to room temperature and extracted with ethyl acetate and water. The organic phase was dried and dried and purified by column chromatography.

(E)-(2-methyl-5-(trifluoromethyl)nona-2,4-dien-4-yl)benzene (8a)




¹**H NMR** (600 MHz, CDCl₃) δ = 7.33 (t, *J* = 7.5 Hz, 2H), 7.28 (d, *J* = 7.5 Hz, 1H), 7.14 (d, *J* = 7.5 Hz, 2H), 6.09 (s, 1H), 2.12 (dd, *J* = 0.12, 7.8 Hz, 2H), 1.76 (s, 3H), 1.34–1.41 (m, 2H), 1.38 (s, 3H), 1.14 (dt, *J* = 14.5, 7.2 Hz, 2H), 0.74 (t, *J* = 7.2 Hz, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 144.77 (q, *J* = 3.9 Hz), 140.96, 137.33, 128.36, 128.31 (q, *J* = 26.1 Hz), 128.19, 127.22, 125.04 (q, *J* = 276.6 Hz), 123.47, 31.60, 28.89, 26.50, 22.46, 19.62, 13.58. ¹⁹**F NMR** (376 MHz, CDCl₃) δ = -58.59 (s). **IR** (KBr, cm⁻¹): 3416, 1623, 1120, 619. **HRMS-APCI**(m/z): [M+H]⁺ calcd. for C₁₇H₂₂F₃, 283.1668; found, 283.1674.

(E)-methyl(2-(2-methyl-5-(trifluoromethyl)nona-2,4-dien-4-yl)phenyl)sulfane (8b)



8b

Colourless oil. ¹**H** NMR (400 MHz, CDCl₃) δ = 7.29 (td, *J* = 7.5, 1.2 Hz, 1H), 7.19 (d, *J* = 7.5 Hz, 1H), 7.12 (td, *J* = 7.5, 1.2 Hz, 1H), 7.03 (dd, *J* = 7.5, 1.2 Hz, 1H), 6.17 (s, 1H), 2.42 (s, 3H), 2.08 (td, *J* = 7.5, 1.2 Hz, 1H), 1.83–1.92 (m, 1H), 1.77 (s, 3H), 1.37– 1.45 (m, 1H), 1.35 (s, 3H), 1.19–1.29 (m, 1H), 1.11 (ddd, *J* = 15.2, 7.5, 3.3 Hz, 2H), 0.70 (t, *J* = 7.2 Hz, 3H). ¹³**C** NMR (100 MHz, CDCl₃) δ = 142.53 (q, *J* = 3.3 Hz), 138.85, 137.88, 136.95, 129.54 (q, *J* = 26.4 Hz), 128.81, 127.94, 124.85 (q, *J* = 275.1 Hz),124.83, 124.50, 121.80, 31.01, 29.07, 27.43, 22.49, 19.30, 15.32, 13.55. ¹⁹**F** NMR (376 MHz, CDCl₃) δ = -58.35 (s). **IR** (KBr, cm⁻¹): 3418, 1633, 1117, 743. **HRMS-APCI**(m/z): [M+H]⁺ calcd. for C₁₈H₂₃F₃S, 329.1545; found, 329.1551. (**E**)-1-ethyl-3-(2-methyl-5-(trifluoromethyl)nona-2,4-dien-4-yl)benzene (8c)



¹**H NMR** (600 MHz, CDCl₃) δ = 7.24 (d, *J* = 7.5 Hz, 1H), 7.10 (d, *J* = 7.2 Hz, 1H), 6.97 (s, 1H), 6.95 (d, *J* = 7.5 Hz, 1H), 6.08 (s, 1H), 2.64 (q, *J* = 7.5 Hz, 2H), 2.10 (dd, *J* = 0.3, 7.8 Hz, 2H), 1.75 (s, 3H), 1.34–1.43 (m, 2H), 1.38 (s, 3H), 1.23 (t, *J* = 7.5 Hz, 3H), 1.15 (dt, *J* = 14.7, 7.5 Hz, 2H), 0.74 (t, *J* = 7.5 Hz, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 145.06 (q, *J* = 3.9 Hz), 144.19, 140.92, 137.12, 128.14, 128.11 (q, *J* = 26.4 Hz), 127.76, 126.75, 125.57, 125.09 (q, *J* = 276.6 Hz), 123.47, 31.73, 28.96, 28.83, 26.53, 22.49, 19.60, 15.61, 13.60. ¹⁹**F NMR** (376 MHz, CDCl₃) δ = -58.65 (s). **IR** (KBr, cm⁻¹): 3420, 2965, 1635, 1329, 1120. **HRMS-APCI**(m/z): [M+H]⁺ calcd. for C₁₉H₂₆F₃, 311.1981; found, 311.1985.

(E)-1-chloro-4-(2-methyl-5-(trifluoromethyl)nona-2,4-dien-4-yl)benzene (8d)




Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.32 (d, *J* = 8.4 Hz, 2H), 7.09 (d, *J* = 8.4 Hz, 2H), 6.07 (s, 1H), 2.11 (dd, *J* = 0.3, 7.8 Hz, 2H), 1.76 (s, 3H), 1.33–1.41 (m, 2H), 1.37 (s, 3H), 1.16 (td, *J* = 15.0, 7.5 Hz, 2H), 0.76 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 143.53 (q, *J* = 3.9 Hz), 139.36, 137.93, 133.20, 129.83, 128.91 (q, *J* = 26.4 Hz), 128.47, 124.83 (q, *J* = 275.1 Hz), 123.15, 31.57, 28.94, 26.47, 22.47, 19.73, 13.61. ¹⁹F NMR (376 MHz, CDCl₃) δ = -58.75 (s). **IR** (KBr, cm⁻¹): 3419, 2963, 1635, 1331, 1121, 741. **HRMS-APCI**(m/z): [M+H]⁺ calcd. for C₁₇H₂₁ClF₃, 317.1278; found, 317.1284.

(E)-1-bromo-4-(2-methyl-5-(trifluoromethyl)nona-2,4-dien-4-yl)benzene (8e)



Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.47 (d, *J* = 8.4 Hz, 2H), 7.03 (d, *J* = 8.4 Hz, 2H), 6.07 (s, 1H), 2.11 (dd, *J* = 0.3, 7.8 Hz, 2H), 1.76 (s, 3H), 1.35–1.41 (m, 2H), 1.37 (s, 3H), 1.16 (td, *J* = 15.0, 7.5 Hz, 2H), 0.77 (t, *J* = 7.5 Hz, 3H). ¹³**C** NMR (150 MHz, CDCl₃) δ = 143.54 (q, *J* = 4.2 Hz), 139.85, 137.95, 131.43, 130.14, 128.92 (q, *J* = 28.5 Hz), 124.81 (q, *J* = 275.1 Hz), 123.07, 121.33, 31.57, 28.94, 26.46, 22.47, 19.75, 13.62. ¹⁹**F** NMR (376 MHz, CDCl₃) δ = -58.90 (s). **IR** (KBr, cm⁻¹): 3416, 1624, 1399, 1116, 617. **HRMS-APCI**(m/z): [M+H]⁺ calcd. for C₁₇H₂₁BrF₃, 361.0773; found, 361.0779.

(E)-4-(2-methyl-5-(trifluoromethyl)nona-2,4-dien-4-yl)benzaldehyde (8f)



Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 10.02 (s, 1H), 7.87 (d, *J* = 8.1 Hz, 2H), 7.34 (d, *J* = 8.1 Hz, 2H), 6.09 (s, 1H), 2.10 (dd, *J* = 0.3, 7.8 Hz, 2H), 1.77 (s, 3H), 1.34– 1.42 (m, 2H), 1.37 (s, 3H), 1.16 (td, *J* = 15.0, 7.5 Hz, 2H), 0.74 (t, *J* = 7.5 Hz, 3H). ¹³**C** NMR (150 MHz, CDCl₃) δ = 191.68, 147.42, 143.53 (q, *J* = 3.9 Hz), 138.48, 135.26, 129.71, 129.49, 129.16, 124.66 (q, *J* = 275.1 Hz), 122.65, 31.49, 28.95, 26.45, 22.44, 19.80, 13.55. ¹⁹**F** NMR (376 MHz, CDCl₃) δ = -57.76 (s). **IR** (KBr, cm⁻¹): 3416, 1706, 1638, 1119, 613. **HRMS-APCI**(m/z): [M+H]⁺ calcd. for C₁₈H₂₂F₃O, 311.1617; found, 311.1622.

(E)-1-(2-methyl-5-(trifluoromethyl)nona-2,4-dien-4-yl)-4-vinylbenzene (8g)



Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.38 (d, *J* = 8.1 Hz, 2H), 7.11 (d, *J* = 8.1 Hz, 2H), 6.71 (dd, *J* = 17.7, 10.8 Hz, 1H), 6.09 (s, 1H), 5.77 (d, *J* = 17.1, 1H), 5.27 (d, *J* = 11.1 Hz, 1H), 2.1 4 (dd, *J* = 0.3, 7.8 Hz, 2H), 1.76 (s, 3H), 1.35–1.43 (m, 2H), 1.38 (s, 3H), 1.16 (dt, *J* = 15.0, 7.5 Hz, 2H), 0.76 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 144.42 (q, *J* = 3.9 Hz), 140.44, 137.53, 136.50, 136.38, 128.65, 128. 37 (q, *J* = 26.1 Hz), 126.05, 125.00 (q, *J* = 275.1 Hz), 123.36, 114.02, 31.65, 28.96, 26.46, 22.49, 19.71, 13.65. ¹⁹F NMR (376 MHz, CDCl₃) δ = -58.57 (s). IR (KBr, cm⁻¹): 3417, 2963, 1632, 1332, 1121, 910, 742. HRMS-APCI(m/z): [M+H]⁺ calcd. for C₁₉H₂₄F₃, 309.1825; found, 309.1829.


(E)-9-(2-methyl-5-(trifluoromethyl)nona-2,4-dien-4-yl)phenanthrene (8h)



Colourless oil. ¹**H** NMR (400 MHz, CDCl₃) δ = 8.73 (d, J = 8.4 Hz, 1H), 8.69 (d, J = 8.1 Hz, 1H), 7.87 (t, J = 7.5 Hz, 2H), 7.66 (dt, J = 8.7, 6.3 Hz, 2H), 7.60 (dd, J = 16.2, 8.1 Hz, 2H), 7.53 (s, 1H), 6.36 (s, 1H), 2.02–2.10 (m, 1H), 1.83–1.86 (m, 1H), 1.74 (s, 3H), 1.29–1.35 (m, 2H), 1.23 (s, 3H), 0.97 (dd, J = 14.5, 7.2 Hz, 2H), 0.56 (t, J = 7.2 Hz, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 142.85 (q, J = 3.9 Hz), 138.56, 136.71, 131.40, 130.47, 130.23, 130.09 (q, J = 25.5 Hz), 129.96, 128.62, 126.88 (q, J = 276.0 Hz), 126.87, 126.84, 126.76, 126.55, 126.29, 126.13, 122.99, 122.65, 122.58, 31.47, 29.59, 27.68, 22.38, 19.53, 13.48. ¹⁹F NMR (376 MHz, CDCl₃) δ = -57.60 (s). HRMS-

ESI(m/z): [M+Na]⁺ calcd. for C₂₅H₂₅F₃Na, 405.1801; found, 405.1803. **IR** (KBr, cm⁻¹): *v*= 3417, 1291, 1630, 1450, 1114, 747.

(E)-2-(2-methyl-5-(trifluoromethyl)nona-2,4-dien-4-yl)anthracene (8i)



¹**H NMR** (600 MHz, CDCl₃) δ = 8.39 (d, *J* = 10.8 Hz, 2H), 7.97–8.02 (m, 3H), 7.77 (s, 1H), 7.44–7.49 (m, 2H), 7.26 (dd, *J* = 8.7, 1.5 Hz, 1H), 6.22 (s, 1H), 2.23 (dd, *J* = 0.3, 7.8 Hz, 2H), 1.79 (s, 3H), 1.45 (td, *J* = 0.3, 7.5 Hz, 2H), 1.41 (s, 3H), 1.12 (dt, *J* = 15.4, 7.5 Hz, 2H), 0.70 (t, *J* = 7.5 Hz, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 144.68 (q, *J* = 4.0 Hz), 138.00, 137.77, 131.98, 131.92, 131.70, 131.24, 130.64, 128.81 (q, *J* = 27.0 Hz), 128.17, 128.08, 127.18, 126.93 (q, *J* = 275.1 Hz), 126.60, 126.40, 125.60, 125.54, 125.33, 123.32, 31.73, 29.08, 26.56, 22.47, 19.81, 13.61. ¹⁹**F NMR** (376 MHz, CDCl₃) δ = -58.57 (s). **IR** (KBr, cm⁻¹): v 3417, 1622, 1326, 1112, 740. **HRMS-APCI**(m/z): [M+H]⁺ calcd. for C₂₅H₂₆F₃, 383.1981; found, 383.1981.

(E)-6-(2-methyl-5-(trifluoromethyl)nona-2,4-dien-4-yl)quinolone (8j)



Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 8.92 (dd, J = 4.2, 1.5 Hz, 1H), 8.14 (d, J = 8.1 Hz, 1H), 8.10 (d, J = 8.7 Hz, 1H), 7.61 (d, J = 0.9 Hz, 1H), 7.54 (dd, J = 8.7, 1.8 Hz, 1H), 7.42 (dd, J = 8.4, 4.2 Hz, 1H), 6.18 (s, 1H), 2.17 (dd, J = 0.3, 7.8 Hz, 2H), 1.78 (s, 3H), 1.41 (dd, J = 12.9, 2.4 Hz, 2H), 1.38 (s, 3H), 1.12 (td, J = 14.7, 7.5 Hz, 2H), 0.71 (t, J = 7.5 Hz, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 150.62, 147.40, 143.93

 $(q, J = 3.9 \text{ Hz}), 139.24, 138.10, 136.04, 130.40, 129.44, 129.29 (q, J = 26.4 \text{ Hz}), 127.96, 126.94, 124.87 (q, J = 275.1 \text{ Hz}), 123.21, 121.47, 31.56, 28.99, 26.44, 22.41, 19.79, 13.55. ¹⁹F NMR (376 MHz, CDCl₃) <math>\delta$ = -58.72. IR (KBr, cm⁻¹): 3416, 2962, 1633, 1322, 1117, 839. HRMS-APCI(m/z): [M+H]⁺ calcd. for C₂₀H₂₃F₃N, 334.1777; found, 334.1773.

(E)-3-(2-methyl-5-(trifluoromethyl)nona-2,4-dien-4-yl)thiophene (8k)



8k

Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.29 (dd, *J* = 4.5, 3.0 Hz, 1H), 7.08 (d, *J* = 1.8 Hz,1H), 6.94 (d, *J* = 4.8 Hz, 1H), 6.10 (s, 1H), 2.23 (dd, *J* = 0.3, 7.8 Hz, 2H), 1.77 (s, 3H), 1.41–1.46 (m, 2H), 1.37 (s, 3H), 1.23 (td, *J* = 14.7, 7.5 Hz, 2H), 0.81 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 140.80, 139.49 (q, *J* = 3.9 Hz), 137.58, 128.57 (q, *J* = 26.1 Hz), 128.37, 125.15, 125.00 (q, *J* = 275.0 Hz), 123.32, 123.26, 31.86, 29.07, 26.30, 22.53, 19.29, 13.64. ¹⁹F NMR (376 MHz, CDCl₃) δ = -58.55 (s). **IR** (KBr, cm⁻¹): 3415, 1622, 1118, 617. **HRMS-APCI**(m/z): [M+H]⁺ calcd. for C₁₅H₂₀F₃S, 289.1232; found, 289.1221.

(E)-3-(2-methyl-5-(trifluoromethyl)nona-2,4-dien-4-yl)benzo[b]thiophene (8l)



Colourless oil. ¹**H NMR** (600 MHz, CDCl₃) δ = 7.81–7.91 (m, 1H), 7.56–7.66 (m, 1H), 7.32–7.41 (m, 2H), 7.17 (s, 1H), 6.09 (s, 1H), 2.05 (dd, J = 0.3, 7.8 Hz, 2H), 1.74 (s, 3H), 1.33 (dt, J = 15.3, 7.5 Hz, 2H), 1.25 (s, 3H), 1.07 (td, J = 14.7, 7.5 Hz, 2H), 0.66 (t, J = 7.5 Hz, 3H). ¹³**C NMR** (150 MHz, CDCl₃) δ = 139.74, 138.88, 138.45 (q, J = 3.9

Hz), 138.01, 136.03, 130.59 (q, J = 26.3 Hz), 124.52, 124.85 (q, J = 275.1 Hz), 124.37, 123.75, 122.87, 122.71, 122.35, 31.72, 29.43, 27.15, 22.29, 19.16, 13.52. ¹⁹F NMR (376 MHz, CDCl₃) $\delta = -58.04$. IR (KBr, cm⁻¹): 3416, 2960, 1636, 1332, 1115, 734. HRMS-APCI(m/z): [M+H]⁺ calcd. For C₁₉H₂₂F₃S, 339.1389; found, 339.1383. (E)-3-(1-cyclohexylidene-3-(trifluoromethyl)hept-2-en-2-yl)benzo[b]thiophene (8m)




Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.82–7.88 (m, 1H), 7.59–7.64 (m, 1H), 7.31–7.39 (m, 2H), 7.18 (s, 1H), 6.17 (s, 1H), 2.10 (dd, *J* = 6.0, 0.06 Hz, 2H), 2.06 (dd, *J* = 7.8, 0.06 Hz, 2H), 1.79 (dd, *J* = 6.0, 0.06 Hz, 2H), 1.50 (dt, *J* = 2.1, 6.0 Hz, 2H), 1.40 (dt, *J* = 1.2, 6.0 Hz, 2H), 1.34 (dt, *J* = 0.18, 7.5 Hz, 2H), 1.13–1.21 (m, 2H), 1.07 (td, *J* = 14.7, 7.5 Hz, 2H), 0.66 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 145.95, 139.78, 138.26 (q, *J* = 3.9 Hz), 137.89, 136.45, 130.75 (q, *J* = 26.1 Hz), 124.86 (q, *J* = 275.1 Hz), 124.50, 124.26, 123.53, 123.05, 122.69, 119.35, 37.86, 31.66, 30.12, 29.45, 28.36, 26.96, 26.30, 22.30, 13.51. ¹⁹F NMR (376 MHz, CDCl₃) δ = -57.92 (s). **IR** (KBr, cm⁻¹): 3458, 2931, 1632, 1112, 742. **HRMS-APCI**(m/z): [M+H]⁺ calcd. for C₂₂H₂₆F₃S, 379.1702; found, 379.1697.

tert-butyl (E)-4-(2-(benzo[b]thiophen-3-yl)-3-(trifluoromethyl)hept-2-en-1ylidene)piperidine-1-carboxylate (8n)



Colourless oil. ¹**H** NMR (600 MHz, CDCl₃) δ = 7.79 – 7.89 (m, 1H), 7.57–7.62 (m, 1H), 7.37 (dd, J = 6.0, 3.1 Hz, 2H), 7.19 (s, 1H), 6.33 (s, 1H), 3.36 (s, 2H), 3.08 – 2.99 (m, 2H), 2.17 (s, 3H), 2.03–2.12 (m, 2H), 1.81 (s, 2H), 1.40 (s, 9H), 1.34 (dt, J = 15.3, 7.6 Hz, 2H), 1.09 (dt, J = 14.8, 7.5 Hz, 2H), 0.67 (t, J = 7.5 Hz, 3H). ¹³C NMR (150 MHz, CDCl₃) δ = 154.56, 141.26 (q, J = 1.5 Hz), 139.82, 137.66, 137.30, 135.88, 131.83 (q, J = 26.4 Hz), 124.72, 124.69 (q, J = 276.0 Hz), 124.44, 123.81, 122.84 (C×2), 121.62, 79.48, 36.61, 31.62, 29.45, 29.44, 28.38, 22.28, 13.48. **IR** (KBr, cm⁻¹): 3415, 1695, 1638, 1423, 1111, 613. **HRMS-APCI**(m/z): [M+H]⁺ calcd. for C₂₆H₃₃F₃NO₂S, 480.2179; found, 480.2188.


(3R,5R,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-((R)-5-oxo-5-(((Z)-1,1,1-trifluoro-5-methyl-3-(thianthren-1-yl)hexa-2,4-dien-2-yl)amino)pentan-2-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl benzoate (80)



¹**H NMR** (600 MHz, CDCl₃) *δ*= 8.05 (d, *J* = 7.5 Hz, 2H), 7.54 (t, *J* = 7.5 Hz, 1H), 7.48 (t, *J* = 7.9 Hz, 3H), 7.43 (t, *J* = 7.7 Hz, 2H), 7.22–7.28 (m, 3H), 7.12 (d, *J* = 7.5 Hz, 1H), 6.23 (s, 1H), 5.32 (brs, 1H), 4.97 (septet, *J* = 5.1 Hz, 1H), 3.96 (quintet, *J* = 7.2 Hz, 1H), 3.68 (dt, *J* = 15.9, 4.2Hz 1H), 2.04–2.08 (m, 1H), 1.93–1.99 (m, 2H), 1.84–1.91 (m, 3H), 1.77–1.83 (m, 2H), 1.80 (s, 3H), 1.66–1.70 (m, 3H), 1.49–1.55 (m, 2H), 1.36–1.47 (m, 4H), 1.30 (s, 3H), 1.15–1.24 (m, 4H), 1.10–1.12 (m, 5H), 0.96 (s, 3H), 0.80–0.88 (m, 5H), 0.63 (d, *J* = 1.9 Hz, 3H). ¹³**C NMR** (150 MHz, CDCl₃) *δ*= 172.63, 166.10, 146.60 (q, *J* = 3.6 Hz), 141.40, 139.18, 136.19 (q, *J* = 2.4 Hz), 135.98, 134.63, 134.15 (q, *J* = 4.5 Hz), 132.63, 130.92, 129.49, 128.71, 128.62, 128.56, 128.21, 128.04, 127.88, 127.79, 127.61, 124.58 (q, *J* = 27.4 Hz), 124.20 (q, *J* = 275.0 Hz), 121.24, 74.98, 56.45, 56.06, 42.71, 41.95, 40.46, 40.13, 37.89, 35.79, 35.37, 35.34, 35.07, 34.63, 33.40,

32.35, 31.54, 31.52, 28.16, 27.65, 27.04, 26.75, 26.32, 24.14, 23.34, 20.85, 19.59, 18.28, 12.01. ¹⁹**F NMR** (376 MHz, CDCl₃) δ = -58.24 (s). **IR** (KBr, cm⁻¹): 3416, 1640, 1273, 1116, 749. **FT-ICR-MS-MALDI**(m/z): [M]⁺ calcd. for C₅₁H₆₀F₃NO₃S₂, 855.39612; found, 855.39594.


(E)-6-methyl-4-(thianthren-1-yl)-3-(trifluoromethyl)hepta-3,5-dien-1-yl-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl) pentanoate (8p)




¹**H NMR** (600 MHz, Acetone) δ = 7.56–7.60 (m, 3H), 7.43 (t, *J* = 7.8 Hz, 1H), 7.33– 7.38 (m, 2H), 7.29 (dd, *J* = 7.5, 0.9 Hz, 1H), 6.26 (brs, 1H), 6.02 (brs, 1H), 5.85 (brs, 1H), 4.48 (dd, *J* = 2.1, 5.1 Hz, 1H), 4.26–4.33 (m, 1H), 3.98 (t, *J* = 6.8 Hz, 2H), 3.14– 3.20 (m, 1H), 2.90–2.93 (m, 1H), 2.69 (d, *J* = 12.5 Hz, 1H), 2.53 (quint, *J* = 6.9 Hz, 1H), 2.34 (quint, *J* = 6.9 Hz, 1H), 2.21 (t, *J* = 7.5 Hz, 2H), 1.78 (s, 3H), 1.69–1.75 (m, 1H), 1.52–1.60 (m, 3H), 1.36–1.40 (m, 2H), 1.35 (s, 3H). ¹³**C NMR** (150 MHz, Acetone) δ = 172.37, 162.93, 145.78 (q, *J* = 3.9 Hz), 139.83, 139.49, 136.38, 135.84, 134.66, 133.98, 128.98, 128.59, 128.42, 128.35, 128.33, 138.23, 127.97, 125.04 (q, *J* = 27.3 Hz), 124.65 (q, *J* = 274.2 Hz), 121.58, 61.65, 61.58, 61.57, 59.92, 55.53, 40.15, 33.33, 28.27, 28.25, 26.46, 24.62, 18.88. **IR** (KBr, cm⁻¹): 3416, 2934, 1712, 1641, 1273,1115, 749. **FT**-**ICR-MS-MALDI**(m/z): [M]⁺ calcd. for C₃₁H₃₃F₃N₂O₃S₃, 634.15999; found, 634.15976.

Mechanism Study


Radical trapped experiments



In an oven-dried 8 mL screwed-capped vial B₂Pin₂ (2.5 mg, 0.01 mmol, 10 mol%), 6,6'dibromo-2,2'-bipyridine (1.8 mg, 0.01 mmol, 10 mol%), **2** (47.4 mg, 0.15 mmol, 1.5 equiv.), radical scavenger (2.0 equiv) were weighted. Then the vial was transferred into the glove-box, CuI (5.7 mg, 0.01 mmol, 30 mol%), **1a** (13.6 mg, 0.1 mmol, 1.0 equiv.) and anhydrous DCE (1.0 mL) were added to the vial. The vial was sealed and moved outside of the glove-box. The vial was kept at 25 °C about 3 hours. After the reaction completion monitored by ¹⁹F NMR and GC-MS.




Control experiments for mechanistic studies




In an oven-dried 8 mL screwed-capped vial B_2Pin_2 (1.8 mg, 0.005 mmol, 10 mol%), 6,6'-dibromo-2,2'-bipyridine (1.5 mg, 0.005 mmol, 10 mol%), 2 (23.7 mg, 0.075 mmol, 1.5 equiv.), 4-A (1.0 equiv, 14.0mg) or 4-B (1.0 equiv, 15.0 mg) were weighted. Then the vial was transferred into the glove-box, CuI (3.0 mg, 0.015 mmol, 30 mol%), 1a (6.8 mg, 0.05 mmol, 1.0 equiv.) and anhydrous DCE (0.6 mL) were added to the vial. The vial was sealed and moved outside of the glove-box. The vial was kept at 25 °C about 8 hours. After the reaction completion monitored by TLC ($R_f = 0.3$, PE), the

reaction was quenched by brine (2 mL), and extracted with EtOAc (5 mL \times 2), the organic solvent was filtrated through a pad of short anhrdrous Na₂SO₄ column. Evaporation and flash Silica gel column purification (petroleum as eluent) of the crude product provided **3a** and **3a'** or **3a''**.



S48




The role of B₂pin₂ in the catalytic protocol

In an oven-dried 8 mL screwed-capped vial "B source" (0.01 mmol, 10 mol%), 6,6'dibromo-2,2'-bipyridine (1.8 mg, 0.01 mmol, 10 mol%), **2** (47.4 mg, 0.15 mmol, 1.5 equiv.), were weighted. Then the vial was transferred into the glove-box, CuI (5.7 mg, 0.03 mmol, 30 mol%), **1a** (13.6 mg, 0.1 mmol, 1.0 equiv.) and anhydrous DCE (0.1 mL) were added to the vial. The vial was sealed and moved outside of the glove-box. The vial was kept at 25 °C about 8 hours. After the reaction completion monitored by TLC ($R_f = 0.3$, PE), the reaction was quenched by brine (2 mL), and extracted with EtOAc (5 mL × 2), the organic solvent was filtrated through a pad of short anhrdrous Na₂SO₄ column. Evaporation and flash Silica gel column purification (petroleum as eluent) of the crude product provided **3a**. Entries 1-4 was followed the same procedure as above. Entries 5,6 was using Zn or Mg (1.0 equiv) instead of B source.


+	CF ₃	Cul (30 mol%) L1 (10 mol%)	
ⁿ Bu		₂ pin ₂ (10 mol%) CE (0.1 M), rt, 8 h	ⁿ Buí Ó Í
1a	2 (1.5 equiv.) "sta	andard conditions"	3а
entry	"B source"		yield (%)
1	B ₂ pin ₂		73%
2	B(OMe) ₃		71%
3	B(OPh) ₃		73%
4	$B(C_6F_5)_3$		67%
5	Zn (1.0 equiv.)		28%
6	Mg (1.0 equiv)		46%

A solution of B₂Pin₂ (6.3 mg,, 50 mol%) in 0.1 mL CDCl₃ was added into a solution of **2** (23.7 mg,, 1.5 equiv.) in 0.4 mL CDCl₃. The vial was kept at 25 °C about 0.5 hours. After the reaction completion monitored by ¹⁹F NMR .



Possible mechanism

Based on the known literature^{5,6}, the reaction mechanism was speculated as shown in the following figure.





References


- Stanek, K.; Koller, R.; Togni, A. Reactivity of a 10-I-3 Hypervalent Iodine Trifluoromethylation Reagent With Phenols. J. Org. Chem. 2008, 73, 7678.
- Qin, Q.; Luo, X.; Wei, J.; Zhu, Y.; Wen, X.; Song, S.; Jiao, N. Acetonitrile Activation: An Effective Two-Carbon Unit for Cyclization. *Angew. Chem. Int. Ed.* 2019, 58, 4376.
- (3) Sun, J.; Yuan, W.; Tian, R.; Wang, P.; Zhang, X.-P.; Li. X. Rhodium(III)-Catalyzed Asymmetric [4+1] and [5+1] Annulation of Arenes and 1,3-Enynes: A Distinct Mechanism of Allyl Formation and Allyl Functionalization. *Angew. Chem. Int. Ed.* 2020, *59*, 22706.
- (4) Sasaki, Y.; Horita, Y.; Zhong, C.; Sawamura, M.; Ito, H. Copper(I)-Catalyzed Regioselective Monoborylation of 1,3-Enynes with an Internal Triple Bond: Selective Synthesis of 1,3-Dienylboronates and 3-Alkynylboronates. *Angew. Chem. Int. Ed.* 2011, *50*, 2778.
- (5) Fu, L.; Greßies, S.; Chen, P.; Liu, G. Recent Advances and Perspectives in Transition Metal-Catalyzed 1,4-Functionalizations of Unactivated 1,3-Enynes for the Synthesis of Allenes. *Chin. J. Chem.* **2020**, *38*, 91.
- (6) Gao, P.; Song, X.-R.; Liu, X.-Y.; Liang, Y.-M. Recent Developments in the Trifluoromethylation of Alkynes *Chem. Eur. J.* 2015, *21*, 7648.


- (7) Amedeo, L.; Gianni, M.; Carlo, R.; Elena, P.; Davide, G.; Marco, L.-M. World Intellectual Property Organization, WO2009015897 A1[P], 2009.
- (8) Gogoi, P., Sigüeiro, R., Eduardo, S. and Mouriño, A. (2010), An Expeditious Route to 1α,25-Dihydroxyvitamin D3 and Its Analogues by an Aqueous Tandem Palladium-Catalyzed A-Ring Closure and Suzuki Coupling to the C/D Unit. *Chem. Eur. J.*, **2010**, *16*: 1432.
- (9) P. Eisenberger, S. Gischig, and A. Togni, Novel 10-I-3 Hypervalent Iodine-Based Compounds for Electrophilic Trifluoromethylation. *Chem. Eur. J.*, **2006**, *12*: 2579.


NMR Spectra






































































100 90 f1 (ppm)


160 150 140 130 120 110


0 190 180 170


70


60 50 40 30 20 10 0 -10


80
































0 190 180 170

160 150


0


-- 100


-10


30 20 10 0


50 40
























































































































































































































10 200 190 180


 -10
























































































































































S144

